statement_id,standardized_cancer,raw_cancer,modified_standardized_cancer,biomarker,therapy
0,invasive breast carcinoma,early breast cancer,early invasive breast carcinoma,"['HER2-negative', 'ER positive']","['Tamoxifen', 'Abemaciclib']"
1,invasive breast carcinoma,early breast cancer,early invasive breast carcinoma,"['PR positive', 'HER2-negative']","['Tamoxifen', 'Abemaciclib']"
2,invasive breast carcinoma,early breast cancer,early invasive breast carcinoma,"['PR positive', 'HER2-negative', 'ER positive']","['Tamoxifen', 'Abemaciclib']"
3,invasive breast carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['HER2-negative', 'ER positive']","['Anastrozole', 'Abemaciclib']"
4,invasive breast carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['PR positive', 'HER2-negative']","['Anastrozole', 'Abemaciclib']"
5,invasive breast carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['PR positive', 'HER2-negative', 'ER positive']","['Anastrozole', 'Abemaciclib']"
6,invasive breast carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['HER2-negative', 'ER positive']","['Abemaciclib', 'Letrozole']"
7,invasive breast carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['PR positive', 'HER2-negative']","['Abemaciclib', 'Letrozole']"
8,invasive breast carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['PR positive', 'HER2-negative', 'ER positive']","['Abemaciclib', 'Letrozole']"
9,invasive breast carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['HER2-negative', 'ER positive']","['Fulvestrant', 'Abemaciclib']"
10,invasive breast carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['PR positive', 'HER2-negative']","['Fulvestrant', 'Abemaciclib']"
11,invasive breast carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['PR positive', 'HER2-negative', 'ER positive']","['Fulvestrant', 'Abemaciclib']"
12,invasive breast carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['HER2-negative', 'ER positive']",['Abemaciclib']
13,invasive breast carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['PR positive', 'HER2-negative']",['Abemaciclib']
14,invasive breast carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['PR positive', 'HER2-negative', 'ER positive']",['Abemaciclib']
15,prostate adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['BARD1 oncogenic variants'],"['Prednisone', 'Niraparib', 'Abiraterone acetate']"
16,prostate adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['BRIP1 oncogenic variants'],"['Prednisone', 'Niraparib', 'Abiraterone acetate']"
17,prostate adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['BRIP1 pathogenic variants'],"['Prednisone', 'Niraparib', 'Abiraterone acetate']"
18,prostate adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['CDK12 pathogenic variants'],"['Prednisone', 'Niraparib', 'Abiraterone acetate']"
19,non-small cell lung cancer,locally advanced or metastatic non-small cell lung cancer,locally advanced or metastatic non-small cell lung cancer,['KRAS p.G12C'],['Adagrasib']
20,invasive breast carcinoma,metastatic breast cancer,metastatic invasive breast carcinoma,['HER2-positive'],['Trastuzumab emtansine']
21,invasive breast carcinoma,early breast cancer,early invasive breast carcinoma,['HER2-positive'],['Trastuzumab emtansine']
22,non-small cell lung cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,['EGFR somatic variants'],['Afatinib']
23,non-small cell lung cancer,non-small cell lung cancer,non-small cell lung cancer,['v::ALK'],['Alectinib']
24,non-small cell lung cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,['v::ALK'],['Alectinib']
25,invasive breast carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['HER2-negative', 'ER positive', 'PIK3CA somatic variants']","['Fulvestrant', 'Alpelisib']"
26,invasive breast carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['PR positive', 'HER2-negative', 'PIK3CA somatic variants']","['Fulvestrant', 'Alpelisib']"
27,invasive breast carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['PR positive', 'HER2-negative', 'ER positive', 'PIK3CA somatic variants']","['Fulvestrant', 'Alpelisib']"
28,non-small cell lung cancer,locally advanced or metastatic non-small cell lung cancer,locally advanced or metastatic non-small cell lung cancer,['EGFR Exon 20 (Insertion)'],"['Carboplatin', 'Amivantamab', 'Pemetrexed']"
29,non-small cell lung cancer,locally advanced or metastatic non-small cell lung cancer,locally advanced or metastatic non-small cell lung cancer,['EGFR Exon 20 (Insertion)'],['Amivantamab']
30,apl with pml-rara,low-risk acute promyelocytic leukemia (apl),low-risk apl with pml-rara,['PML::RARA'],['Arsenic trioxide']
31,apl with pml-rara,acute promyelocytic leukemia (apl),apl with pml-rara,['PML::RARA'],['Arsenic trioxide']
32,chronic myelogenous leukemia,philadelphia chromosome-positive chronic myeloid leukemia (ph+ cml),philadelphia chromosome-positive chronic myelogenous leukemia,['BCR::ABL1'],['Asciminib']
33,chronic myelogenous leukemia,philadelphia chromosome-positive chronic myeloid leukemia (ph+ cml),philadelphia chromosome-positive chronic myelogenous leukemia,"['ABL1 p.T315I', 'BCR::ABL1']",['Asciminib']
34,non-small cell lung cancer,non-small cell lung cancer,non-small cell lung cancer,['PD-L1 >= 1%'],['Atezolizumab']
35,non-small cell lung cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,['PD-L1 >= 50%'],['Atezolizumab']
36,non-small cell lung cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,['PD-L1 >= 10% TIIC'],['Atezolizumab']
37,non-small cell lung cancer,metastatic non-squamous non-small cell lung cancer,metastatic non-squamous non-small cell lung cancer,"['Wild type EGFR', 'Wild type ALK']","['Carboplatin', 'Paclitaxel', 'Bevacizumab', 'Atezolizumab']"
38,non-small cell lung cancer,metastatic non-squamous non-small cell lung cancer,metastatic non-squamous non-small cell lung cancer,"['Wild type EGFR', 'Wild type ALK']","['Carboplatin', 'Paclitaxel', 'Atezolizumab']"
39,non-small cell lung cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,['EGFR somatic variants'],['Atezolizumab']
40,non-small cell lung cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,['v::ALK'],['Atezolizumab']
41,melanoma,unresectable or metastatic melanoma,unresectable or metastatic melanoma,['BRAF p.V600E'],"['Vemurafenib', 'Cobimetinib', 'Atezolizumab']"
42,melanoma,unresectable or metastatic melanoma,unresectable or metastatic melanoma,['BRAF p.V600K'],"['Vemurafenib', 'Cobimetinib', 'Atezolizumab']"
43,gastrointestinal stromal tumor,unresectable or metastatic gist,unresectable or metastatic gastrointestinal stromal tumor,['PDGFRA p.D842V'],['Avapritinib']
44,melanoma,unresectable or metastatic melanoma,unresectable or metastatic melanoma,['BRAF p.V600E'],"['Binimetinib', 'Encorafenib']"
45,melanoma,unresectable or metastatic melanoma,unresectable or metastatic melanoma,['BRAF p.V600K'],"['Binimetinib', 'Encorafenib']"
46,non-small cell lung cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,['BRAF p.V600E'],"['Binimetinib', 'Encorafenib']"
47,invasive breast carcinoma,early breast cancer,early invasive breast carcinoma,"['PR positive', 'HER2-negative', 'ER positive']","['Abemaciclib', 'Letrozole']"
48,acute lymphoid leukemia,b-cell precursor acute lymphoblastic leukemia (all),b-cell precursor acute lymphoid leukemia,['CD19 +'],['Blinatumomab']
49,acute lymphoid leukemia,b-cell precursor acute lymphoblastic leukemia (all),b-cell precursor acute lymphoid leukemia,['CD19 +'],['Blinatumomab']
50,acute lymphoid leukemia,b-cell precusor acute lymphoblastic leukemia (all),b-cell acute lymphoid leukemia,"['BCR::ABL1', 'CD19 +']",['Blinatumomab']
51,chronic myelogenous leukemia,philadelphia chromosome-positive chronic myelogenous leukemia (cml),philadelphia chromosome-positive chronic myelogenous leukemia,['BCR::ABL1'],['Bosutinib']
52,chronic myelogenous leukemia,philadelphia chromosome-positive chronic myelogenous leukemia (cml),philadelphia chromosome-positive chronic myelogenous leukemia,['BCR::ABL1'],['Bosutinib']
54,anaplastic large cell lymphoma,"systemic anaplastic large cell lymphoma (salcl) or other cd30-expressing peripheral t-cell lymphomas (ptcl), including angioimmunoblastic t-cell lymphoma and ptcl not otherwise specified",systemic anaplastic large cell lymphoma,['CD30 +'],"['Doxorubicin', 'Prednisone', 'Brentuximab vedotin', 'Cyclophosphamide']"
55,anaplastic large cell lymphoma,cutaneous analastplci large cell lymphoma (pcalcl) or cd30-expressing mycosis fungoides (mf),cutaneous anaplastic large cell lymphoma,['CD30 +'],['Brentuximab vedotin']
56,non-small cell lung cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,['v::ALK'],['Brigatinib']
57,adenocarcinoma of the gastroesophageal junction,metastatic gastric or gastroesophageal junction adenocarcinoma,metastatic adenocarcinoma of the gastroesophageal junction,['HER2-positive'],['Capecitabine']
58,invasive breast carcinoma,locally advanced or metastatic breast cancer,locally advanced or metastatic invasive breast carcinoma,"['HER2-negative', 'ER positive', 'PIK3CA somatic variants']","['Fulvestrant', 'Capivasertib']"
59,invasive breast carcinoma,locally advanced or metastatic breast cancer,locally advanced or metastatic invasive breast carcinoma,"['PR positive', 'HER2-negative', 'PIK3CA somatic variants']","['Fulvestrant', 'Capivasertib']"
60,invasive breast carcinoma,locally advanced or metastatic breast cancer,locally advanced or metastatic invasive breast carcinoma,"['PR positive', 'HER2-negative', 'ER positive', 'PIK3CA somatic variants']","['Fulvestrant', 'Capivasertib']"
61,invasive breast carcinoma,locally advanced or metastatic breast cancer,locally advanced or metastatic invasive breast carcinoma,"['AKT1 somatic variants', 'HER2-negative', 'ER positive']","['Fulvestrant', 'Capivasertib']"
62,invasive breast carcinoma,locally advanced or metastatic breast cancer,locally advanced or metastatic invasive breast carcinoma,"['PR positive', 'AKT1 somatic variants', 'HER2-negative']","['Fulvestrant', 'Capivasertib']"
63,invasive breast carcinoma,locally advanced or metastatic breast cancer,locally advanced or metastatic invasive breast carcinoma,"['PR positive', 'AKT1 somatic variants', 'HER2-negative', 'ER positive']","['Fulvestrant', 'Capivasertib']"
64,invasive breast carcinoma,locally advanced or metastatic breast cancer,locally advanced or metastatic invasive breast carcinoma,"['AKT1 amplification', 'HER2-negative', 'ER positive']","['Fulvestrant', 'Capivasertib']"
65,invasive breast carcinoma,locally advanced or metastatic breast cancer,locally advanced or metastatic invasive breast carcinoma,"['AKT1 amplification', 'PR positive', 'HER2-negative']","['Fulvestrant', 'Capivasertib']"
66,invasive breast carcinoma,locally advanced or metastatic breast cancer,locally advanced or metastatic invasive breast carcinoma,"['AKT1 amplification', 'PR positive', 'HER2-negative', 'ER positive']","['Fulvestrant', 'Capivasertib']"
67,invasive breast carcinoma,locally advanced or metastatic breast cancer,locally advanced or metastatic invasive breast carcinoma,"['PTEN nonsense variants', 'HER2-negative', 'ER positive']","['Fulvestrant', 'Capivasertib']"
68,invasive breast carcinoma,locally advanced or metastatic breast cancer,locally advanced or metastatic invasive breast carcinoma,"['PTEN nonsense variants', 'PR positive', 'HER2-negative']","['Fulvestrant', 'Capivasertib']"
69,invasive breast carcinoma,locally advanced or metastatic breast cancer,locally advanced or metastatic invasive breast carcinoma,"['PTEN nonsense variants', 'PR positive', 'HER2-negative', 'ER positive']","['Fulvestrant', 'Capivasertib']"
70,invasive breast carcinoma,locally advanced or metastatic breast cancer,locally advanced or metastatic invasive breast carcinoma,"['PTEN frameshift variants', 'HER2-negative', 'ER positive']","['Fulvestrant', 'Capivasertib']"
71,invasive breast carcinoma,locally advanced or metastatic breast cancer,locally advanced or metastatic invasive breast carcinoma,"['PTEN frameshift variants', 'PR positive', 'HER2-negative']","['Fulvestrant', 'Capivasertib']"
72,invasive breast carcinoma,locally advanced or metastatic breast cancer,locally advanced or metastatic invasive breast carcinoma,"['PTEN frameshift variants', 'PR positive', 'HER2-negative', 'ER positive']","['Fulvestrant', 'Capivasertib']"
73,invasive breast carcinoma,locally advanced or metastatic breast cancer,locally advanced or metastatic invasive breast carcinoma,"['PTEN splice site variants', 'HER2-negative', 'ER positive']","['Fulvestrant', 'Capivasertib']"
74,invasive breast carcinoma,locally advanced or metastatic breast cancer,locally advanced or metastatic invasive breast carcinoma,"['PTEN splice site variants', 'PR positive', 'HER2-negative']","['Fulvestrant', 'Capivasertib']"
75,invasive breast carcinoma,locally advanced or metastatic breast cancer,locally advanced or metastatic invasive breast carcinoma,"['PTEN splice site variants', 'PR positive', 'HER2-negative', 'ER positive']","['Fulvestrant', 'Capivasertib']"
76,invasive breast carcinoma,locally advanced or metastatic breast cancer,locally advanced or metastatic invasive breast carcinoma,"['HER2-negative', 'ER positive', 'PTEN deletion']","['Fulvestrant', 'Capivasertib']"
77,invasive breast carcinoma,locally advanced or metastatic breast cancer,locally advanced or metastatic invasive breast carcinoma,"['PR positive', 'HER2-negative', 'PTEN deletion']","['Fulvestrant', 'Capivasertib']"
78,invasive breast carcinoma,locally advanced or metastatic breast cancer,locally advanced or metastatic invasive breast carcinoma,"['PR positive', 'HER2-negative', 'ER positive', 'PTEN deletion']","['Fulvestrant', 'Capivasertib']"
79,non-small cell lung cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,['MET Exon 14 (Splice Site)'],['Capmatinib']
80,non-small cell lung cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,['MET Exon 14 (Deletion)'],['Capmatinib']
81,non-small cell lung cancer,non-small cell lung cancer,non-small cell lung cancer,"['Wild type EGFR', 'Wild type ALK', 'Wild type ROS1']","['Carboplatin', 'Cemiplimab', 'Pemetrexed']"
82,non-small cell lung cancer,non-small cell lung cancer,non-small cell lung cancer,"['dMMR', 'Wild type EGFR', 'Wild type ALK', 'PD-L1 >= 50%']",['Cemiplimab']
83,non-small cell lung cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,['v::ALK'],['Ceritinib']
84,colorectal adenocarcinoma,metastatic colorectal cancer,metastatic colorectal adenocarcinoma,"['EGFR positive', 'Wild type KRAS']","['Fluorouracil', 'Irinotecan', 'Cetuximab']"
85,colorectal adenocarcinoma,metastatic colorectal cancer,metastatic colorectal adenocarcinoma,"['EGFR positive', 'Wild type KRAS']","['Irinotecan', 'Cetuximab']"
86,colorectal adenocarcinoma,metastatic colorectal cancer,metastatic colorectal adenocarcinoma,"['EGFR positive', 'Wild type KRAS']",['Cetuximab']
87,colorectal adenocarcinoma,metastatic colorectal cancer,metastatic colorectal adenocarcinoma,['BRAF p.V600E'],"['Cetuximab', 'Encorafenib']"
88,melanoma,unresectable or metastatic melanoma,unresectable or metastatic melanoma,['BRAF p.V600E'],"['Vemurafenib', 'Cobimetinib']"
89,melanoma,unresectable or metastatic melanoma,unresectable or metastatic melanoma,['BRAF p.V600K'],"['Vemurafenib', 'Cobimetinib']"
90,non-small cell lung cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,['v::ALK'],['Crizotinib']
91,non-small cell lung cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,['v::ROS1'],['Crizotinib']
92,anaplastic large cell lymphoma,anaplastic large cell lymphoma (alcl),anaplastic large cell lymphoma,['v::ALK'],['Crizotinib']
93,inflammatory myofibroblastic tumor,"unresectable, recurrent, or refractory inflammatory myofibroblastic tumor (imt)","unresectable, recurrent, or refractory inflammatory myofibroblastic tumor",['v::ALK'],['Crizotinib']
94,melanoma,unresectable or metastatic melanoma,unresectable or metastatic melanoma,['BRAF p.V600E'],['Dabrafenib']
95,melanoma,unresectable or metastatic melanoma,unresectable or metastatic melanoma,['BRAF p.V600E'],"['Trametinib', 'Dabrafenib']"
96,melanoma,unresectable or metastatic melanoma,unresectable or metastatic melanoma,['BRAF p.V600K'],"['Trametinib', 'Dabrafenib']"
97,melanoma,melanoma,melanoma,['BRAF p.V600E'],"['Trametinib', 'Dabrafenib']"
98,melanoma,melanoma,melanoma,['BRAF p.V600K'],"['Trametinib', 'Dabrafenib']"
99,invasive breast carcinoma,early breast cancer,early invasive breast carcinoma,"['HER2-negative', 'ER positive']","['Abemaciclib', 'Letrozole']"
100,non-small cell lung cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,['BRAF p.V600E'],"['Trametinib', 'Dabrafenib']"
101,anaplastic thyroid cancer,locally advanced or metastatic anaplastic thyroid cancer (atc),locally advanced or metastatic anaplastic thyroid cancer,['BRAF p.V600E'],"['Trametinib', 'Dabrafenib']"
102,any solid tumor,unresectable or metastatic solid tumors,unresectable or metastatic any solid tumor,['BRAF p.V600E'],"['Trametinib', 'Dabrafenib']"
103,"low-grade glioma, nos",low-grade glioma (lgg),"low-grade glioma, nos",['BRAF p.V600E'],"['Trametinib', 'Dabrafenib']"
104,non-small cell lung cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,['EGFR Exon 19 (Deletion)'],['Dacomitinib']
105,non-small cell lung cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,['EGFR p.L858R'],['Dacomitinib']
106,chronic myelogenous leukemia,philadelphia chromosome-positive (ph+) chronic myeloid leukemia (cml),philadelphia chromosome-positive chronic myelogenous leukemia,['BCR::ABL1'],['Dasatinib']
107,"chronic myeloid leukemia, bcr-abl1+",philadelphia chromosome-positive (ph+) chronic myeloid leukemia (cml),"philadelphia chromosome-positive chronic myeloid leukemia, bcr-abl1+",['BCR::ABL1'],['Dasatinib']
108,chronic myelogenous leukemia,"chronic, accelerated, or myeloid or lymphoid blast phase ph+ cml","chronic, accelerated, or myeloid or lymphoid blast phase ph+ chronic myelogenous leukemia",['BCR::ABL1'],['Dasatinib']
109,"chronic myeloid leukemia, bcr-abl1+","chronic, accelerated, or myeloid or lymphoid blast phase ph+ cml","chronic, accelerated, or myeloid or lymphoid blast phase ph+ chronic myeloid leukemia, bcr-abl1+",['BCR::ABL1'],['Dasatinib']
110,acute lymphoid leukemia,philadelphia chromosome-positive acute lymphoblastic leukemia (ph+ all),philadelphia chromosome-positive acute lymphoid leukemia,['BCR::ABL1'],['Dasatinib']
111,chronic myelogenous leukemia,philadelphia chromosome-positive cml,philadelphia chromosome-positive chronic myelogenous leukemia,['BCR::ABL1'],['Dasatinib']
112,"chronic myeloid leukemia, bcr-abl1+",philadelphia chromosome-positive cml,"philadelphia chromosome-positive chronic myeloid leukemia, bcr-abl1+",['BCR::ABL1'],['Dasatinib']
113,acute lymphoid leukemia,philadelphia chromosome-positive all,philadelphia chromosome-positive acute lymphoid leukemia,['BCR::ABL1'],['Dasatinib']
114,endometrial carcinoma,primary advanced or recurrent endometrial cancer,primary advanced or recurrent endometrial carcinoma,['dMMR'],"['Carboplatin', 'Dostarlimab', 'Paclitaxel']"
115,endometrial carcinoma,primary advanced or recurrent endometrial cancer,primary advanced or recurrent endometrial carcinoma,['MSI-H'],"['Carboplatin', 'Dostarlimab', 'Paclitaxel']"
116,endometrial carcinoma,recurrent or advanced endometrial cancer,recurrent or advanced endometrial carcinoma,['dMMR'],['Dostarlimab']
117,any solid tumor,recurrent or advanced solid tumors,recurrent or advanced any solid tumor,['dMMR'],['Dostarlimab']
118,non-small cell lung cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,"['Wild type EGFR', 'Wild type ALK']","['Tremelimumab', 'Carboplatin', 'Durvalumab', 'Pemetrexed']"
119,non-small cell lung cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,"['Wild type EGFR', 'Wild type ALK']","['Tremelimumab', 'Durvalumab', 'Pemetrexed', 'Cisplatin']"
120,non-small cell lung cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,"['Wild type EGFR', 'Wild type ALK']","['Tremelimumab', 'Carboplatin', 'Durvalumab', 'Gemcitabine']"
121,non-small cell lung cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,"['Wild type EGFR', 'Wild type ALK']","['Tremelimumab', 'Durvalumab', 'Gemcitabine', 'Cisplatin']"
122,non-small cell lung cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,"['Wild type EGFR', 'Wild type ALK']","['Tremelimumab', 'Carboplatin', 'Durvalumab', 'Nab-paclitaxel']"
123,endometrial carcinoma,primary advanced or recurrent endometrial cancer,primary advanced or recurrent endometrial carcinoma,['dMMR'],"['Carboplatin', 'Paclitaxel', 'Durvalumab']"
124,invasive breast carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['ESR1 oncogenic variants', 'HER2-negative', 'ER positive']",['Elacestrant']
125,acute myeloid leukemia,relapsed or refractory acute myeloid leukemia (aml),relapsed or refractory acute myeloid leukemia,['IDH2 p.R140Q'],['Enasidenib']
126,acute myeloid leukemia,relapsed or refractory acute myeloid leukemia (aml),relapsed or refractory acute myeloid leukemia,['IDH2 p.R140L'],['Enasidenib']
127,acute myeloid leukemia,relapsed or refractory acute myeloid leukemia (aml),relapsed or refractory acute myeloid leukemia,['IDH2 p.R140G'],['Enasidenib']
128,acute myeloid leukemia,relapsed or refractory acute myeloid leukemia (aml),relapsed or refractory acute myeloid leukemia,['IDH2 p.R140W'],['Enasidenib']
129,acute myeloid leukemia,relapsed or refractory acute myeloid leukemia (aml),relapsed or refractory acute myeloid leukemia,['IDH2 p.R172K'],['Enasidenib']
130,acute myeloid leukemia,relapsed or refractory acute myeloid leukemia (aml),relapsed or refractory acute myeloid leukemia,['IDH2 p.R172M'],['Enasidenib']
131,acute myeloid leukemia,relapsed or refractory acute myeloid leukemia (aml),relapsed or refractory acute myeloid leukemia,['IDH2 p.R172G'],['Enasidenib']
132,acute myeloid leukemia,relapsed or refractory acute myeloid leukemia (aml),relapsed or refractory acute myeloid leukemia,['IDH2 p.R172S'],['Enasidenib']
133,acute myeloid leukemia,relapsed or refractory acute myeloid leukemia (aml),relapsed or refractory acute myeloid leukemia,['IDH2 p.R172W'],['Enasidenib']
134,melanoma,unresectable or metastatic melanoma,unresectable or metastatic melanoma,['BRAF p.V600E'],"['Binimetinib', 'Encorafenib']"
135,melanoma,unresectable or metastatic melanoma,unresectable or metastatic melanoma,['BRAF p.V600K'],"['Binimetinib', 'Encorafenib']"
136,colorectal adenocarcinoma,metastatic colorectal cancer,metastatic colorectal adenocarcinoma,['BRAF p.V600E'],"['Cetuximab', 'Encorafenib']"
137,non-small cell lung cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,['BRAF p.V600E'],"['Binimetinib', 'Encorafenib']"
138,non-small cell lung cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,['v::ROS1'],['Entrectinib']
139,any solid tumor,solid tumors,any solid tumor,['v::NTRK1'],['Entrectinib']
140,any solid tumor,solid tumors,any solid tumor,['v::NTRK2'],['Entrectinib']
141,any solid tumor,solid tumors,any solid tumor,['v::NTRK3'],['Entrectinib']
142,bladder urothelial carcinoma,locally advanced or metastatic urothelial carcinoma (muc),locally advanced or metastatic bladder urothelial carcinoma,['FGFR3 p.R248C'],['Erdafitinib']
143,bladder urothelial carcinoma,locally advanced or metastatic urothelial carcinoma (muc),locally advanced or metastatic bladder urothelial carcinoma,['FGFR3 p.S249C'],['Erdafitinib']
144,bladder urothelial carcinoma,locally advanced or metastatic urothelial carcinoma (muc),locally advanced or metastatic bladder urothelial carcinoma,['FGFR3 p.G370C'],['Erdafitinib']
145,bladder urothelial carcinoma,locally advanced or metastatic urothelial carcinoma (muc),locally advanced or metastatic bladder urothelial carcinoma,['FGFR3 p.Y373C'],['Erdafitinib']
146,bladder urothelial carcinoma,locally advanced or metastatic urothelial carcinoma (muc),locally advanced or metastatic bladder urothelial carcinoma,['FGFR3::TACC3'],['Erdafitinib']
147,non-small cell lung cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,['EGFR Exon 19 (Deletion)'],['Erlotinib']
148,non-small cell lung cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,['EGFR p.L858R'],['Erlotinib']
149,invasive breast carcinoma,breast cancer,invasive breast carcinoma,"['HER2-negative', 'ER positive']","['Exemestane', 'Everolimus']"
150,invasive breast carcinoma,breast cancer,invasive breast carcinoma,"['PR positive', 'HER2-negative']","['Exemestane', 'Everolimus']"
151,invasive breast carcinoma,breast cancer,invasive breast carcinoma,"['PR positive', 'HER2-negative', 'ER positive']","['Exemestane', 'Everolimus']"
152,invasive breast carcinoma,breast cancer,invasive breast carcinoma,"['HER2-negative', 'ER positive']",['Fulvestrant']
153,invasive breast carcinoma,breast cancer,invasive breast carcinoma,"['PR positive', 'HER2-negative']",['Fulvestrant']
154,invasive breast carcinoma,breast cancer,invasive breast carcinoma,"['PR positive', 'HER2-negative', 'ER positive']",['Fulvestrant']
155,invasive breast carcinoma,breast cancer,invasive breast carcinoma,['ER positive'],['Fulvestrant']
156,invasive breast carcinoma,breast cancer,invasive breast carcinoma,['PR positive'],['Fulvestrant']
157,invasive breast carcinoma,breast cancer,invasive breast carcinoma,"['PR positive', 'ER positive']",['Fulvestrant']
158,invasive breast carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['HER2-negative', 'ER positive']","['Fulvestrant', 'Ribociclib']"
159,invasive breast carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['PR positive', 'HER2-negative']","['Fulvestrant', 'Ribociclib']"
160,invasive breast carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['PR positive', 'HER2-negative', 'ER positive']","['Fulvestrant', 'Ribociclib']"
161,invasive breast carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['HER2-negative', 'ER positive']","['Fulvestrant', 'Palbociclib']"
162,invasive breast carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['PR positive', 'HER2-negative']","['Fulvestrant', 'Palbociclib']"
163,invasive breast carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['PR positive', 'HER2-negative', 'ER positive']","['Fulvestrant', 'Palbociclib']"
164,invasive breast carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['HER2-negative', 'ER positive']","['Fulvestrant', 'Abemaciclib']"
165,invasive breast carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['PR positive', 'HER2-negative']","['Fulvestrant', 'Abemaciclib']"
166,invasive breast carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['PR positive', 'HER2-negative', 'ER positive']","['Fulvestrant', 'Abemaciclib']"
167,intrahepatic cholangiocarcinoma,"unresectable, locally or metastatic intrahepatic cholangiocarcinoma","unresectable, locally or metastatic intrahepatic cholangiocarcinoma",['FGFR2::v'],['Futibatinib']
168,non-small cell lung cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,['EGFR Exon 19 (Deletion)'],['Gefitinib']
169,non-small cell lung cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,['EGFR p.L858R'],['Gefitinib']
170,acute lymphoid leukemia,acute myeloid leukemia,acute lymphoid leukemia,['CD33 +'],['Gemtuzumab ozogamicin']
171,acute lymphoid leukemia,acute myeloid leukemia,acute lymphoid leukemia,['CD33 +'],['Gemtuzumab ozogamicin']
172,acute lymphoid leukemia,relapsed or refractory acute myeloid leukemia,relapsed or refractory acute lymphoid leukemia,['FLT3-ITD'],['Gilteritinib']
173,acute lymphoid leukemia,relapsed or refractory acute myeloid leukemia,relapsed or refractory acute lymphoid leukemia,['FLT3 p.D835Y'],['Gilteritinib']
174,acute lymphoid leukemia,relapsed or refractory acute myeloid leukemia,relapsed or refractory acute lymphoid leukemia,['FLT3 p.D835A'],['Gilteritinib']
175,acute lymphoid leukemia,relapsed or refractory acute myeloid leukemia,relapsed or refractory acute lymphoid leukemia,['FLT3 p.D835E'],['Gilteritinib']
176,acute lymphoid leukemia,relapsed or refractory acute myeloid leukemia,relapsed or refractory acute lymphoid leukemia,['FLT3 p.D835H'],['Gilteritinib']
177,acute lymphoid leukemia,relapsed or refractory acute myeloid leukemia,relapsed or refractory acute lymphoid leukemia,['FLT3 p.D835N'],['Gilteritinib']
178,acute lymphoid leukemia,relapsed or refractory acute myeloid leukemia,relapsed or refractory acute lymphoid leukemia,['FLT3 p.D835S'],['Gilteritinib']
179,acute lymphoid leukemia,relapsed or refractory acute myeloid leukemia,relapsed or refractory acute lymphoid leukemia,['FLT3 p.D835V'],['Gilteritinib']
180,chronic myelogenous leukemia,philadelphia chromosome-positive chronic myeloid leukemia,philadelphia chromosome-positive chronic myelogenous leukemia,['BCR::ABL1'],['Imatinib']
181,"chronic myeloid leukemia, bcr-abl1+",philadelphia chromosome-positive chronic myeloid leukemia,"philadelphia chromosome-positive chronic myeloid leukemia, bcr-abl1+",['BCR::ABL1'],['Imatinib']
182,chronic myelogenous leukemia,philadelphia chromosome-positive chronic myeloid leukemia,philadelphia chromosome-positive chronic myelogenous leukemia,['BCR::ABL1'],['Imatinib']
183,"chronic myeloid leukemia, bcr-abl1+",philadelphia chromosome-positive chronic myeloid leukemia,"philadelphia chromosome-positive chronic myeloid leukemia, bcr-abl1+",['BCR::ABL1'],['Imatinib']
184,acute lymphoid leukemia,philadelphia chromosome-positive acute lymphoblastic leukemia,philadelphia chromosome-positive acute lymphoid leukemia,['BCR::ABL1'],['Imatinib']
185,acute lymphoid leukemia,philadelphia chromosome-positive acute lymphoblastic leukemia,philadelphia chromosome-positive acute lymphoid leukemia,['BCR::ABL1'],['Imatinib']
186,myelodysplastic syndromes,myelodyplastic/myeloproliferative diseases (mds/mpd),myelodysplastic syndromes,['PDGFRA rearrangements'],['Imatinib']
187,myelodysplastic syndromes,myelodyplastic/myeloproliferative diseases (mds/mpd),myelodysplastic syndromes,['PDGFRB rearrangements'],['Imatinib']
188,aggressive systemic mastocytosis,aggressive systemic mastocytosis (asm),aggressive systemic mastocytosis,['KIT p.D816V'],['Imatinib']
189,"chronic eosinophilic leukemia, nos",hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukemia (cel),"chronic eosinophilic leukemia, nos",['FIP1L1::PDGFRA'],['Imatinib']
190,gastrointestinal stromal tumor,unresectable and/or metastatic maligant gastrointestinal stromal tumors (gist),unresectable and/or metastatic maligant gastrointestinal stromal tumor,['CD117 +'],['Imatinib']
191,gastrointestinal stromal tumor,gist,gastrointestinal stromal tumor,['FIP1L1::PDGFRA'],['Imatinib']
192,cholangiocarcinoma,unresectable locally advanced or metastatic cholangiocarcinoma,unresectable locally advanced or metastatic cholangiocarcinoma,['FGFR2::v'],['Infigratinib']
193,acute lymphoid leukemia,b-cell precursor acute lymphoblastic leukemia (all),b-cell precursor acute lymphoid leukemia,['CD22 +'],['Inotuzumab ozogamicin']
194,colorectal adenocarcinoma,metastatic colorectal cancer,metastatic colorectal adenocarcinoma,['MSI-H'],"['Nivolumab', 'Ipilimumab']"
195,colorectal adenocarcinoma,metastatic colorectal cancer,metastatic colorectal adenocarcinoma,['dMMR'],"['Nivolumab', 'Ipilimumab']"
196,non-small cell lung cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,"['Wild type EGFR', 'Wild type ALK', 'PD-L1 >= 1%']","['Nivolumab', 'Ipilimumab']"
197,non-small cell lung cancer,metastatic or recurrent non-small cell lung cancer,metastatic or recurrent non-small cell lung cancer,"['Wild type EGFR', 'Wild type ALK']","['Carboplatin', 'Nivolumab', 'Ipilimumab', 'Pemetrexed']"
198,non-small cell lung cancer,metastatic or recurrent non-small cell lung cancer,metastatic or recurrent non-small cell lung cancer,"['Wild type EGFR', 'Wild type ALK']","['Nivolumab', 'Ipilimumab', 'Pemetrexed', 'Cisplatin']"
199,non-small cell lung cancer,metastatic or recurrent non-small cell lung cancer,metastatic or recurrent non-small cell lung cancer,"['Wild type EGFR', 'Wild type ALK']","['Carboplatin', 'Paclitaxel', 'Nivolumab', 'Ipilimumab']"
200,acute myeloid leukemia,acute myeloid leukemia,acute myeloid leukemia,['IDH1 p.R132C'],['Ivosidenib']
201,acute myeloid leukemia,acute myeloid leukemia,acute myeloid leukemia,['IDH1 p.R132G'],['Ivosidenib']
202,acute myeloid leukemia,acute myeloid leukemia,acute myeloid leukemia,['IDH1 p.R132H'],['Ivosidenib']
203,acute myeloid leukemia,acute myeloid leukemia,acute myeloid leukemia,['IDH1 p.R132L'],['Ivosidenib']
204,acute myeloid leukemia,acute myeloid leukemia,acute myeloid leukemia,['IDH1 p.R132S'],['Ivosidenib']
205,acute myeloid leukemia,acute myeloid leukemia,acute myeloid leukemia,['IDH1 p.R132C'],"['Ivosidenib', 'Azacitidine']"
206,acute myeloid leukemia,acute myeloid leukemia,acute myeloid leukemia,['IDH1 p.R132G'],"['Ivosidenib', 'Azacitidine']"
207,acute myeloid leukemia,acute myeloid leukemia,acute myeloid leukemia,['IDH1 p.R132H'],"['Ivosidenib', 'Azacitidine']"
208,acute myeloid leukemia,acute myeloid leukemia,acute myeloid leukemia,['IDH1 p.R132L'],"['Ivosidenib', 'Azacitidine']"
209,acute myeloid leukemia,acute myeloid leukemia,acute myeloid leukemia,['IDH1 p.R132S'],"['Ivosidenib', 'Azacitidine']"
210,acute myeloid leukemia,relapsed or refractory aml,relapsed or refractory acute myeloid leukemia,['IDH1 p.R132C'],['Ivosidenib']
211,acute myeloid leukemia,relapsed or refractory aml,relapsed or refractory acute myeloid leukemia,['IDH1 p.R132G'],['Ivosidenib']
212,acute myeloid leukemia,relapsed or refractory aml,relapsed or refractory acute myeloid leukemia,['IDH1 p.R132H'],['Ivosidenib']
213,acute myeloid leukemia,relapsed or refractory aml,relapsed or refractory acute myeloid leukemia,['IDH1 p.R132L'],['Ivosidenib']
214,acute myeloid leukemia,relapsed or refractory aml,relapsed or refractory acute myeloid leukemia,['IDH1 p.R132S'],['Ivosidenib']
215,myelodysplastic syndromes,relapsed or refractory myelodysplastic syndromes,relapsed or refractory myelodysplastic syndromes,['IDH1 p.R132C'],['Ivosidenib']
216,myelodysplastic syndromes,relapsed or refractory myelodysplastic syndromes,relapsed or refractory myelodysplastic syndromes,['IDH1 p.R132G'],['Ivosidenib']
217,myelodysplastic syndromes,relapsed or refractory myelodysplastic syndromes,relapsed or refractory myelodysplastic syndromes,['IDH1 p.R132H'],['Ivosidenib']
218,myelodysplastic syndromes,relapsed or refractory myelodysplastic syndromes,relapsed or refractory myelodysplastic syndromes,['IDH1 p.R132L'],['Ivosidenib']
219,myelodysplastic syndromes,relapsed or refractory myelodysplastic syndromes,relapsed or refractory myelodysplastic syndromes,['IDH1 p.R132S'],['Ivosidenib']
220,cholangiocarcinoma,locally advanced or metastatic cholangiocarcinoma,locally advanced or metastatic cholangiocarcinoma,['IDH1 p.R132C'],['Ivosidenib']
221,cholangiocarcinoma,locally advanced or metastatic cholangiocarcinoma,locally advanced or metastatic cholangiocarcinoma,['IDH1 p.R132G'],['Ivosidenib']
222,cholangiocarcinoma,locally advanced or metastatic cholangiocarcinoma,locally advanced or metastatic cholangiocarcinoma,['IDH1 p.R132H'],['Ivosidenib']
223,cholangiocarcinoma,locally advanced or metastatic cholangiocarcinoma,locally advanced or metastatic cholangiocarcinoma,['IDH1 p.R132L'],['Ivosidenib']
224,cholangiocarcinoma,locally advanced or metastatic cholangiocarcinoma,locally advanced or metastatic cholangiocarcinoma,['IDH1 p.R132S'],['Ivosidenib']
225,invasive breast carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,['HER2-positive'],"['Lapatinib', 'Capecitabine']"
226,invasive breast carcinoma,metastatic breast cancer,metastatic invasive breast carcinoma,"['HER2-positive', 'ER positive']","['Lapatinib', 'Letrozole']"
227,invasive breast carcinoma,metastatic breast cancer,metastatic invasive breast carcinoma,"['HER2-positive', 'PR positive']","['Lapatinib', 'Letrozole']"
228,invasive breast carcinoma,metastatic breast cancer,metastatic invasive breast carcinoma,"['HER2-positive', 'PR positive', 'ER positive']","['Lapatinib', 'Letrozole']"
229,any solid tumor,solid tumors,any solid tumor,['v::NTRK1'],['Larotrectinib']
230,any solid tumor,solid tumors,any solid tumor,['v::NTRK2'],['Larotrectinib']
231,any solid tumor,solid tumors,any solid tumor,['v::NTRK3'],['Larotrectinib']
232,myelodysplastic syndromes,transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (mds),transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes,['5q deletion'],['Lenalidomide']
233,non-small cell lung cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,['v::ALK'],['Lorlatinib']
234,invasive breast carcinoma,metastatic breast cancer,metastatic invasive breast carcinoma,['HER2-positive'],"['Margetuximab', 'Capecitabine']"
235,invasive breast carcinoma,metastatic breast cancer,metastatic invasive breast carcinoma,['HER2-positive'],"['Eribulin', 'Margetuximab']"
236,invasive breast carcinoma,metastatic breast cancer,metastatic invasive breast carcinoma,['HER2-positive'],"['Margetuximab', 'Gemcitabine']"
237,invasive breast carcinoma,metastatic breast cancer,metastatic invasive breast carcinoma,['HER2-positive'],"['Margetuximab', 'Vinorelbine']"
238,acute myeloid leukemia,acute myeloid leukemia,acute myeloid leukemia,['FLT3-ITD'],"['Midostaurin', 'Daunorubicin', 'Cytarabine']"
239,acute myeloid leukemia,acute myeloid leukemia,acute myeloid leukemia,['FLT3 p.D835Y'],"['Midostaurin', 'Daunorubicin', 'Cytarabine']"
240,acute myeloid leukemia,acute myeloid leukemia,acute myeloid leukemia,['FLT3 p.D835A'],"['Midostaurin', 'Daunorubicin', 'Cytarabine']"
241,acute myeloid leukemia,acute myeloid leukemia,acute myeloid leukemia,['FLT3 p.D835E'],"['Midostaurin', 'Daunorubicin', 'Cytarabine']"
242,acute myeloid leukemia,acute myeloid leukemia,acute myeloid leukemia,['FLT3 p.D835H'],"['Midostaurin', 'Daunorubicin', 'Cytarabine']"
243,acute myeloid leukemia,acute myeloid leukemia,acute myeloid leukemia,['FLT3 p.D835N'],"['Midostaurin', 'Daunorubicin', 'Cytarabine']"
244,acute myeloid leukemia,acute myeloid leukemia,acute myeloid leukemia,['FLT3 p.D835S'],"['Midostaurin', 'Daunorubicin', 'Cytarabine']"
245,acute myeloid leukemia,acute myeloid leukemia,acute myeloid leukemia,['FLT3 p.D835V'],"['Midostaurin', 'Daunorubicin', 'Cytarabine']"
246,acute myeloid leukemia,acute myeloid leukemia,acute myeloid leukemia,['FLT3 p.I836del'],"['Midostaurin', 'Daunorubicin', 'Cytarabine']"
247,acute myeloid leukemia,acute myeloid leukemia,acute myeloid leukemia,['CDK12 oncogenic variants'],"['Midostaurin', 'Daunorubicin', 'Cytarabine']"
248,non-small cell lung cancer,locally advanced or metastatic non-small cell lung cancer,locally advanced or metastatic non-small cell lung cancer,['EGFR Exon 20 (Insertion)'],['Mobocertinib']
249,invasive breast carcinoma,early-stage breast cancer,early-stage invasive breast carcinoma,['HER2-positive'],['Neratinib']
250,invasive breast carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,['HER2-positive'],"['Capecitabine', 'Neratinib']"
251,chronic myelogenous leukemia,philadelphia chromosome-positive chronic myeloid (ph+ cml),philadelphia chromosome-positive chronic myelogenous leukemia,['BCR::ABL1'],['Nilotinib']
252,"chronic myeloid leukemia, bcr-abl1+",philadelphia chromosome-positive chronic myeloid (ph+ cml),"philadelphia chromosome-positive chronic myeloid leukemia, bcr-abl1+",['BCR::ABL1'],['Nilotinib']
253,chronic myelogenous leukemia,chronic phase or accelerated phase ph+ cml,chronic phase or accelerated phase ph+ chronic myelogenous leukemia,['BCR::ABL1'],['Nilotinib']
254,"chronic myeloid leukemia, bcr-abl1+",chronic phase or accelerated phase ph+ cml,"chronic phase or accelerated phase ph+ chronic myeloid leukemia, bcr-abl1+",['BCR::ABL1'],['Nilotinib']
255,ovarian epithelial tumor,"recurrent epithelial ovarian, fallopian tubem or primary peritoneal cancer",recurrent ovarian epithelial tumor,['BRCA1 pathogenic variants'],['Niraparib']
256,ovarian epithelial tumor,"recurrent epithelial ovarian, fallopian tubem or primary peritoneal cancer",recurrent ovarian epithelial tumor,['BRCA2 pathogenic variants'],['Niraparib']
257,high-grade serous fallopian tube cancer,"recurrent epithelial ovarian, fallopian tubem or primary peritoneal cancer",recurrent high-grade serous fallopian tube cancer,['BRCA1 pathogenic variants'],['Niraparib']
258,high-grade serous fallopian tube cancer,"recurrent epithelial ovarian, fallopian tubem or primary peritoneal cancer",recurrent high-grade serous fallopian tube cancer,['BRCA2 pathogenic variants'],['Niraparib']
259,peritoneal serous carcinoma,"recurrent epithelial ovarian, fallopian tubem or primary peritoneal cancer",recurrent peritoneal serous carcinoma,['BRCA1 pathogenic variants'],['Niraparib']
260,peritoneal serous carcinoma,"recurrent epithelial ovarian, fallopian tubem or primary peritoneal cancer",recurrent peritoneal serous carcinoma,['BRCA2 pathogenic variants'],['Niraparib']
261,non-small cell lung cancer,non-small cell lung cancer,non-small cell lung cancer,"['Wild type EGFR', 'Wild type ALK']","['Carboplatin', 'Paclitaxel', 'Nivolumab']"
262,non-small cell lung cancer,non-small cell lung cancer,non-small cell lung cancer,['PD-L1 >= 1%'],"['Nivolumab', 'Ipilimumab']"
263,ovarian epithelial tumor,"advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",advanced ovarian epithelial tumor,['BRCA1 oncogenic variants'],['Olaparib']
264,ovarian epithelial tumor,"advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",advanced ovarian epithelial tumor,['BRCA1 pathogenic variants'],['Olaparib']
265,ovarian epithelial tumor,"advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",advanced ovarian epithelial tumor,['BRCA2 oncogenic variants'],['Olaparib']
266,ovarian epithelial tumor,"advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",advanced ovarian epithelial tumor,['BRCA2 pathogenic variants'],['Olaparib']
267,high-grade serous fallopian tube cancer,"advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",advanced high-grade serous fallopian tube cancer,['BRCA1 oncogenic variants'],['Olaparib']
268,high-grade serous fallopian tube cancer,"advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",advanced high-grade serous fallopian tube cancer,['BRCA1 pathogenic variants'],['Olaparib']
269,high-grade serous fallopian tube cancer,"advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",advanced high-grade serous fallopian tube cancer,['BRCA2 oncogenic variants'],['Olaparib']
270,high-grade serous fallopian tube cancer,"advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",advanced high-grade serous fallopian tube cancer,['BRCA2 pathogenic variants'],['Olaparib']
271,peritoneal serous carcinoma,"advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",advanced peritoneal serous carcinoma,['BRCA1 oncogenic variants'],['Olaparib']
272,peritoneal serous carcinoma,"advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",advanced peritoneal serous carcinoma,['BRCA1 pathogenic variants'],['Olaparib']
273,peritoneal serous carcinoma,"advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",advanced peritoneal serous carcinoma,['BRCA2 oncogenic variants'],['Olaparib']
274,peritoneal serous carcinoma,"advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",advanced peritoneal serous carcinoma,['BRCA2 pathogenic variants'],['Olaparib']
275,ovarian epithelial tumor,"advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",advanced ovarian epithelial tumor,['BRCA1 oncogenic variants'],"['Olaparib', 'Bevacizumab']"
276,ovarian epithelial tumor,"advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",advanced ovarian epithelial tumor,['BRCA1 pathogenic variants'],"['Olaparib', 'Bevacizumab']"
277,ovarian epithelial tumor,"advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",advanced ovarian epithelial tumor,['BRCA2 oncogenic variants'],"['Olaparib', 'Bevacizumab']"
278,ovarian epithelial tumor,"advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",advanced ovarian epithelial tumor,['BRCA2 pathogenic variants'],"['Olaparib', 'Bevacizumab']"
279,ovarian epithelial tumor,"advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",advanced ovarian epithelial tumor,['HRD'],"['Olaparib', 'Bevacizumab']"
280,high-grade serous fallopian tube cancer,"advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",advanced high-grade serous fallopian tube cancer,['BRCA1 oncogenic variants'],"['Olaparib', 'Bevacizumab']"
281,high-grade serous fallopian tube cancer,"advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",advanced high-grade serous fallopian tube cancer,['BRCA1 pathogenic variants'],"['Olaparib', 'Bevacizumab']"
282,high-grade serous fallopian tube cancer,"advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",advanced high-grade serous fallopian tube cancer,['BRCA2 oncogenic variants'],"['Olaparib', 'Bevacizumab']"
283,high-grade serous fallopian tube cancer,"advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",advanced high-grade serous fallopian tube cancer,['BRCA2 pathogenic variants'],"['Olaparib', 'Bevacizumab']"
284,high-grade serous fallopian tube cancer,"advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",advanced high-grade serous fallopian tube cancer,['HRD'],"['Olaparib', 'Bevacizumab']"
285,peritoneal serous carcinoma,"advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",advanced peritoneal serous carcinoma,['BRCA1 oncogenic variants'],"['Olaparib', 'Bevacizumab']"
286,peritoneal serous carcinoma,"advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",advanced peritoneal serous carcinoma,['BRCA1 pathogenic variants'],"['Olaparib', 'Bevacizumab']"
287,peritoneal serous carcinoma,"advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",advanced peritoneal serous carcinoma,['BRCA2 oncogenic variants'],"['Olaparib', 'Bevacizumab']"
288,peritoneal serous carcinoma,"advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",advanced peritoneal serous carcinoma,['BRCA2 pathogenic variants'],"['Olaparib', 'Bevacizumab']"
289,peritoneal serous carcinoma,"advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",advanced peritoneal serous carcinoma,['HRD'],"['Olaparib', 'Bevacizumab']"
290,ovarian epithelial tumor,"relapsed epithelial ovarian, fallopian tube or primary peritoneal cancer",relapsed ovarian epithelial tumor,['BRCA1 oncogenic variants'],['Olaparib']
291,ovarian epithelial tumor,"relapsed epithelial ovarian, fallopian tube or primary peritoneal cancer",relapsed ovarian epithelial tumor,['BRCA1 pathogenic variants'],['Olaparib']
292,ovarian epithelial tumor,"relapsed epithelial ovarian, fallopian tube or primary peritoneal cancer",relapsed ovarian epithelial tumor,['BRCA2 oncogenic variants'],['Olaparib']
293,ovarian epithelial tumor,"relapsed epithelial ovarian, fallopian tube or primary peritoneal cancer",relapsed ovarian epithelial tumor,['BRCA2 pathogenic variants'],['Olaparib']
294,high-grade serous fallopian tube cancer,"relapsed epithelial ovarian, fallopian tube or primary peritoneal cancer",relapsed high-grade serous fallopian tube cancer,['BRCA1 oncogenic variants'],['Olaparib']
295,high-grade serous fallopian tube cancer,"relapsed epithelial ovarian, fallopian tube or primary peritoneal cancer",relapsed high-grade serous fallopian tube cancer,['BRCA1 pathogenic variants'],['Olaparib']
296,high-grade serous fallopian tube cancer,"relapsed epithelial ovarian, fallopian tube or primary peritoneal cancer",relapsed high-grade serous fallopian tube cancer,['BRCA2 oncogenic variants'],['Olaparib']
297,high-grade serous fallopian tube cancer,"relapsed epithelial ovarian, fallopian tube or primary peritoneal cancer",relapsed high-grade serous fallopian tube cancer,['BRCA2 pathogenic variants'],['Olaparib']
298,peritoneal serous carcinoma,"relapsed epithelial ovarian, fallopian tube or primary peritoneal cancer",relapsed peritoneal serous carcinoma,['BRCA1 oncogenic variants'],['Olaparib']
299,peritoneal serous carcinoma,"relapsed epithelial ovarian, fallopian tube or primary peritoneal cancer",relapsed peritoneal serous carcinoma,['BRCA1 pathogenic variants'],['Olaparib']
300,peritoneal serous carcinoma,"relapsed epithelial ovarian, fallopian tube or primary peritoneal cancer",relapsed peritoneal serous carcinoma,['BRCA2 oncogenic variants'],['Olaparib']
301,peritoneal serous carcinoma,"relapsed epithelial ovarian, fallopian tube or primary peritoneal cancer",relapsed peritoneal serous carcinoma,['BRCA2 pathogenic variants'],['Olaparib']
302,invasive breast carcinoma,high risk early breast cancer,high risk early invasive breast carcinoma,"['HER2-negative', 'BRCA1 pathogenic variants']",['Olaparib']
303,invasive breast carcinoma,high risk early breast cancer,high risk early invasive breast carcinoma,"['HER2-negative', 'BRCA2 pathogenic variants']",['Olaparib']
304,invasive breast carcinoma,metastatic breast cancer,metastatic invasive breast carcinoma,"['HER2-negative', 'BRCA1 pathogenic variants']",['Olaparib']
305,invasive breast carcinoma,metastatic breast cancer,metastatic invasive breast carcinoma,"['HER2-negative', 'BRCA2 pathogenic variants']",['Olaparib']
306,pancreatic adenocarcinoma,metastatic pancreatic adenocarcinoma,metastatic pancreatic adenocarcinoma,['BRCA1 pathogenic variants'],['Olaparib']
307,pancreatic adenocarcinoma,metastatic pancreatic adenocarcinoma,metastatic pancreatic adenocarcinoma,['BRCA2 pathogenic variants'],['Olaparib']
308,prostate adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['BRCA1 oncogenic variants'],"['Enzalutamide', 'Talazoparib']"
309,prostate adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['BRCA1 oncogenic variants'],['Olaparib']
310,prostate adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['BRCA1 pathogenic variants'],['Olaparib']
311,prostate adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['BRCA2 oncogenic variants'],['Olaparib']
312,prostate adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['BRCA2 pathogenic variants'],['Olaparib']
313,prostate adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['ATM pathogenic variants'],['Olaparib']
314,prostate adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['ATM oncogenic variants'],['Olaparib']
315,prostate adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['BARD1 pathogenic variants'],['Olaparib']
316,prostate adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['BARD1 oncogenic variants'],['Olaparib']
317,prostate adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['BRIP1 oncogenic variants'],['Olaparib']
318,prostate adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['BRIP1 pathogenic variants'],['Olaparib']
319,prostate adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['CDK12 pathogenic variants'],['Olaparib']
320,prostate adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['CDK12 oncogenic variants'],['Olaparib']
321,prostate adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['CHEK1 pathogenic variants'],['Olaparib']
322,prostate adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['CHEK1 oncogenic variants'],['Olaparib']
323,prostate adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['CHEK2 pathogenic variants'],['Olaparib']
324,prostate adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['CHEK2 oncogenic variants'],['Olaparib']
325,prostate adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['FANCL pathogenic variants'],['Olaparib']
326,prostate adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['FANCL oncogenic variants'],['Olaparib']
327,prostate adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['PALB2 pathogenic variants'],['Olaparib']
328,prostate adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['PALB2 oncogenic variants'],['Olaparib']
329,prostate adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['RAD51B pathogenic variants'],['Olaparib']
330,prostate adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['RAD51B oncogenic variants'],['Talazoparib']
331,prostate adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['RAD51C pathogenic variants'],['Olaparib']
332,prostate adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['RAD51C oncogenic variants'],['Olaparib']
333,prostate adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['RAD51D pathogenic variants'],['Olaparib']
334,prostate adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['RAD51D oncogenic variants'],['Olaparib']
335,prostate adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['RAD54L pathogenic variants'],['Olaparib']
336,prostate adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['RAD54L oncogenic variants'],['Olaparib']
337,prostate adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['BRCA1 oncogenic variants'],"['Prednisolone', 'Olaparib', 'Abiraterone acetate']"
338,prostate adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['BRCA1 pathogenic variants'],"['Prednisolone', 'Olaparib', 'Abiraterone acetate']"
339,prostate adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['BRCA2 oncogenic variants'],"['Prednisolone', 'Olaparib', 'Abiraterone acetate']"
340,prostate adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['BRCA2 pathogenic variants'],"['Prednisolone', 'Olaparib', 'Abiraterone acetate']"
341,prostate adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['BRCA1 oncogenic variants'],"['Prednisone', 'Olaparib', 'Abiraterone acetate']"
342,prostate adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['BRCA1 pathogenic variants'],"['Prednisone', 'Olaparib', 'Abiraterone acetate']"
343,prostate adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['BRCA2 oncogenic variants'],"['Prednisone', 'Olaparib', 'Abiraterone acetate']"
344,prostate adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['BRCA2 pathogenic variants'],"['Prednisone', 'Olaparib', 'Abiraterone acetate']"
345,acute myeloid leukemia,relapsed or refractory acute myeloid leukemia (aml),relapsed or refractory acute myeloid leukemia,['IDH1 p.R132C'],['Olutasidenib']
346,acute myeloid leukemia,relapsed or refractory acute myeloid leukemia (aml),relapsed or refractory acute myeloid leukemia,['IDH1 p.R132G'],['Olutasidenib']
347,acute myeloid leukemia,relapsed or refractory acute myeloid leukemia (aml),relapsed or refractory acute myeloid leukemia,['IDH1 p.R132H'],['Olutasidenib']
348,acute myeloid leukemia,relapsed or refractory acute myeloid leukemia (aml),relapsed or refractory acute myeloid leukemia,['IDH1 p.R132L'],['Olutasidenib']
349,acute myeloid leukemia,relapsed or refractory acute myeloid leukemia (aml),relapsed or refractory acute myeloid leukemia,['IDH1 p.R132S'],['Olutasidenib']
350,non-small cell lung cancer,non-small cell lung cancer,non-small cell lung cancer,['EGFR Exon 19 (Deletion)'],['Osimertinib']
351,non-small cell lung cancer,non-small cell lung cancer,non-small cell lung cancer,['EGFR p.L858R'],['Osimertinib']
352,non-small cell lung cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,['EGFR p.L858R'],['Osimertinib']
353,non-small cell lung cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,['EGFR Exon 19 (Deletion)'],['Osimertinib']
354,non-small cell lung cancer,locally advanced or metastatic non-small cell lung cancer,locally advanced or metastatic non-small cell lung cancer,['EGFR p.L858R'],"['Osimertinib', 'Pemetrexed', 'Cisplatin']"
355,non-small cell lung cancer,locally advanced or metastatic non-small cell lung cancer,locally advanced or metastatic non-small cell lung cancer,['EGFR p.L858R'],"['Carboplatin', 'Osimertinib', 'Pemetrexed']"
356,non-small cell lung cancer,locally advanced or metastatic non-small cell lung cancer,locally advanced or metastatic non-small cell lung cancer,['EGFR Exon 19 (Deletion)'],"['Carboplatin', 'Osimertinib', 'Pemetrexed']"
357,non-small cell lung cancer,locally advanced or metastatic non-small cell lung cancer,locally advanced or metastatic non-small cell lung cancer,['EGFR Exon 19 (Deletion)'],"['Osimertinib', 'Pemetrexed', 'Cisplatin']"
358,non-small cell lung cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,['EGFR p.T790M'],['Osimertinib']
359,invasive breast carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['HER2-negative', 'ER positive']","['Palbociclib', 'Letrozole']"
360,invasive breast carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['PR positive', 'HER2-negative']","['Palbociclib', 'Letrozole']"
361,invasive breast carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['PR positive', 'HER2-negative', 'ER positive']","['Palbociclib', 'Letrozole']"
362,invasive breast carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['HER2-negative', 'ER positive']","['Fulvestrant', 'Palbociclib']"
363,invasive breast carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['PR positive', 'HER2-negative']","['Fulvestrant', 'Palbociclib']"
364,invasive breast carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['PR positive', 'HER2-negative', 'ER positive']","['Fulvestrant', 'Palbociclib']"
365,colorectal adenocarcinoma,metastatic colorectal cancer,metastatic colorectal adenocarcinoma,"['Wild type KRAS', 'Wild type HRAS']","['Panitumumab', 'Oxaliplatin', 'Fluorouracil']"
366,colorectal adenocarcinoma,metastatic colorectal cancer,metastatic colorectal adenocarcinoma,"['Wild type KRAS', 'Wild type HRAS']",['Panitumumab']
367,non-small cell lung cancer,metastatic non-squamous non-small cell lung cancer,metastatic non-squamous non-small cell lung cancer,"['Wild type EGFR', 'Wild type ALK']","['Carboplatin', 'Pemetrexed', 'Pembrolizumab']"
368,non-small cell lung cancer,metastatic non-squamous non-small cell lung cancer,metastatic non-squamous non-small cell lung cancer,"['Wild type EGFR', 'Wild type ALK']","['Pemetrexed', 'Cisplatin', 'Pembrolizumab']"
369,non-small cell lung cancer,non-small cell lung cancer,non-small cell lung cancer,"['Wild type EGFR', 'Wild type ALK', 'PD-L1 >= 1%']",['Pembrolizumab']
370,non-small cell lung cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,['PD-L1 >= 1%'],['Pembrolizumab']
371,head and neck squamous cell carcinoma,"metastatic or unresectable, recurrent hnscc","metastatic or unresectable, recurrent head and neck squamous cell carcinoma",['PD-L1 (CPS) >= 1'],['Pembrolizumab']
372,any solid tumor,unresectable or metastatic ... solid tumors,unresectable or metastatic any solid tumor,['dMMR'],['Pembrolizumab']
373,any solid tumor,unresectable or metastatic ... solid tumors,unresectable or metastatic any solid tumor,['MSI-H'],['Pembrolizumab']
374,colorectal adenocarcinoma,unresectable or metastatic ... colorectal cancer,unresectable or metastatic colorectal adenocarcinoma,['dMMR'],['Pembrolizumab']
375,colorectal adenocarcinoma,unresectable or metastatic ... colorectal cancer,unresectable or metastatic colorectal adenocarcinoma,['MSI-H'],['Pembrolizumab']
376,adenocarcinoma of the gastroesophageal junction,locally advanced unresectable or metastatic ... gastric or gastroesophageal junction (gej) adenocracinoma,locally advanced unresectable or metastatic adenocarcinoma of the gastroesophageal junction,"['HER2-positive', 'PD-L1 (CPS) >= 1']","['Trastuzumab', 'Fluorouracil', 'Cisplatin', 'Pembrolizumab']"
377,adenocarcinoma of the gastroesophageal junction,locally advanced unresectable or metastatic ... gastric or gastroesophageal junction (gej) adenocracinoma,locally advanced unresectable or metastatic adenocarcinoma of the gastroesophageal junction,"['HER2-positive', 'PD-L1 (CPS) >= 1']","['Trastuzumab', 'Oxaliplatin', 'Capecitabine', 'Pembrolizumab']"
378,adenocarcinoma of the gastroesophageal junction,locally advanced unresectable or metastatic ... gastric or gastroesophageal junction (gej) adenocarcinoma,locally advanced unresectable or metastatic adenocarcinoma of the gastroesophageal junction,['HER2-negative'],"['Fluorouracil', 'Cisplatin', 'Pembrolizumab']"
379,adenocarcinoma of the gastroesophageal junction,locally advanced unresectable or metastatic ... gastric or gastroesophageal junction (gej) adenocarcinoma,locally advanced unresectable or metastatic adenocarcinoma of the gastroesophageal junction,['HER2-negative'],"['Oxaliplatin', 'Capecitabine', 'Pembrolizumab']"
380,adenocarcinoma of the gastroesophageal junction,locally advanced or metastatic esophageal or gastroesophageal junction carcinoma,locally advanced or metastatic adenocarcinoma of the gastroesophageal junction,['PD-L1 (CPS) >= 10'],['Pembrolizumab']
381,esophageal adenocarcinoma,locally advanced or metastatic esophageal or gastroesophageal junction carcinoma,locally advanced or metastatic esophageal adenocarcinoma,['PD-L1 (CPS) >= 10'],['Pembrolizumab']
382,cervical adenocarcinoma,"persistent, recurrent, or metastatic cervical cancer","persistent, recurrent, or metastatic cervical adenocarcinoma",['PD-L1 (CPS) >= 1'],"['Paclitaxel', 'Cisplatin', 'Pembrolizumab']"
383,cervical squamous cell carcinoma,"persistent, recurrent, or metastatic cervical cancer","persistent, recurrent, or metastatic cervical squamous cell carcinoma",['PD-L1 (CPS) >= 1'],"['Paclitaxel', 'Cisplatin', 'Pembrolizumab']"
384,cervical adenocarcinoma,"persistent, recurrent, or metastatic cervical cancer","persistent, recurrent, or metastatic cervical adenocarcinoma",['PD-L1 (CPS) >= 1'],"['Paclitaxel', 'Bevacizumab', 'Cisplatin', 'Pembrolizumab']"
385,cervical squamous cell carcinoma,"persistent, recurrent, or metastatic cervical cancer","persistent, recurrent, or metastatic cervical squamous cell carcinoma",['PD-L1 (CPS) >= 1'],"['Paclitaxel', 'Bevacizumab', 'Cisplatin', 'Pembrolizumab']"
386,cervical adenocarcinoma,"persistent, recurrent, or metastatic cervical cancer","persistent, recurrent, or metastatic cervical adenocarcinoma",['PD-L1 (CPS) >= 1'],"['Carboplatin', 'Paclitaxel', 'Pembrolizumab']"
387,cervical squamous cell carcinoma,"persistent, recurrent, or metastatic cervical cancer","persistent, recurrent, or metastatic cervical squamous cell carcinoma",['PD-L1 (CPS) >= 1'],"['Carboplatin', 'Paclitaxel', 'Pembrolizumab']"
388,cervical adenocarcinoma,"persistent, recurrent, or metastatic cervical cancer","persistent, recurrent, or metastatic cervical adenocarcinoma",['PD-L1 (CPS) >= 1'],"['Carboplatin', 'Paclitaxel', 'Bevacizumab', 'Pembrolizumab']"
389,cervical squamous cell carcinoma,"persistent, recurrent, or metastatic cervical cancer","persistent, recurrent, or metastatic cervical squamous cell carcinoma",['PD-L1 (CPS) >= 1'],"['Carboplatin', 'Paclitaxel', 'Bevacizumab', 'Pembrolizumab']"
390,cervical adenocarcinoma,recurrent or metastatic cervical cancer,recurrent or metastatic cervical adenocarcinoma,['PD-L1 (CPS) >= 1'],['Pembrolizumab']
391,cervical squamous cell carcinoma,recurrent or metastatic cervical cancer,recurrent or metastatic cervical squamous cell carcinoma,['PD-L1 (CPS) >= 1'],['Pembrolizumab']
392,endometrial carcinoma,advanced endometrial carcinoma,advanced endometrial carcinoma,['MSI-L'],"['Lenvatinib', 'Pembrolizumab']"
393,endometrial carcinoma,advanced endometrial carcinoma,advanced endometrial carcinoma,['pMMR'],['Pembrolizumab']
394,endometrial carcinoma,advanced endometrial carcinoma,advanced endometrial carcinoma,['MSI-H'],['Pembrolizumab']
395,any solid tumor,unresectable or metastatic ... solid tumors,unresectable or metastatic any solid tumor,['TMB-H (>= 10 mutations / Mb)'],['Pembrolizumab']
396,invasive breast carcinoma,high-risk early-stage triple-negative breast cancer,high-risk early-stage triple-negative invasive breast carcinoma,"['ER negative', 'PR negative', 'HER2-negative']","['Carboplatin', 'Doxorubicin', 'Paclitaxel', 'Cyclophosphamide', 'Pembrolizumab']"
397,invasive breast carcinoma,locally recurrent unresectable or metastatic triple-negative breast cancer,locally recurrent unresectable or metastatic triple-negative invasive breast carcinoma,"['ER negative', 'PR negative', 'HER2-negative', 'PD-L1 (CPS) >= 10']","['Paclitaxel', 'Pembrolizumab']"
398,invasive breast carcinoma,locally recurrent unresectable or metastatic triple-negative breast cancer,locally recurrent unresectable or metastatic triple-negative invasive breast carcinoma,"['ER negative', 'PR negative', 'HER2-negative', 'PD-L1 (CPS) >= 10']","['Carboplatin', 'Gemcitabine', 'Pembrolizumab']"
399,cholangiocarcinoma,unresectable locally advanced or metastatic cholangiocarcinoma,unresectable locally advanced or metastatic cholangiocarcinoma,['FGFR2::v'],['Pemigatinib']
400,cholangiocarcinoma,unresectable locally advanced or metastatic cholangiocarcinoma,unresectable locally advanced or metastatic cholangiocarcinoma,['FGFR2 rearrangements'],['Pemigatinib']
401,myeloid/lymphoid neoplasms,relapsed or refractory myeloid/lymphoid neoplasms (mlns),relapsed or refractory myeloid/lymphoid neoplasms,['FGFR1 rearrangements'],['Pemigatinib']
402,invasive breast carcinoma,metastatic breast cancer,metastatic invasive breast carcinoma,['HER2-positive'],"['Trastuzumab', 'Docetaxel', 'Pertuzumab']"
403,invasive breast carcinoma,"locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive)","locally advanced, inflammatory, or early stage invasive breast carcinoma",['HER2-positive'],"['Trastuzumab', 'Doxorubicin', 'Paclitaxel', 'Pertuzumab', 'Cyclophosphamide']"
404,invasive breast carcinoma,"locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive)","locally advanced, inflammatory, or early stage invasive breast carcinoma",['HER2-positive'],"['Trastuzumab', 'Fluorouracil', 'Docetaxel', 'Pertuzumab', 'Epirubicin', 'Cyclophosphamide']"
405,invasive breast carcinoma,metastatic breast cancer,metastatic invasive breast carcinoma,['HER2-positive'],"['Trastuzumab', 'Docetaxel', 'Pertuzumab']"
406,invasive breast carcinoma,early stage breast cancer,early stage invasive breast carcinoma,['HER2-positive'],"['Trastuzumab', 'Fluorouracil', 'Paclitaxel', 'Pertuzumab', 'Epirubicin', 'Cyclophosphamide']"
407,invasive breast carcinoma,early stage breast cancer,early stage invasive breast carcinoma,['HER2-positive'],"['Trastuzumab', 'Doxorubicin', 'Fluorouracil', 'Docetaxel', 'Pertuzumab', 'Cyclophosphamide']"
408,invasive breast carcinoma,early stage breast cancer,early stage invasive breast carcinoma,['HER2-positive'],"['Trastuzumab', 'Doxorubicin', 'Fluorouracil', 'Paclitaxel', 'Pertuzumab', 'Cyclophosphamide']"
409,invasive breast carcinoma,early stage breast cancer,early stage invasive breast carcinoma,['HER2-positive'],"['Trastuzumab', 'Docetaxel', 'Pertuzumab', 'Epirubicin', 'Cyclophosphamide']"
410,invasive breast carcinoma,early stage breast cancer,early stage invasive breast carcinoma,['HER2-positive'],"['Trastuzumab', 'Paclitaxel', 'Pertuzumab', 'Epirubicin', 'Cyclophosphamide']"
411,invasive breast carcinoma,early stage breast cancer,early stage invasive breast carcinoma,['HER2-positive'],"['Trastuzumab', 'Doxorubicin', 'Docetaxel', 'Pertuzumab', 'Cyclophosphamide']"
412,invasive breast carcinoma,early breast cancer,early invasive breast carcinoma,['HER2-positive'],"['Trastuzumab', 'Fluorouracil', 'Docetaxel', 'Pertuzumab', 'Epirubicin', 'Cyclophosphamide']"
413,invasive breast carcinoma,early stage breast cancer,early stage invasive breast carcinoma,['HER2-positive'],"['Trastuzumab', 'Carboplatin', 'Docetaxel', 'Pertuzumab']"
414,invasive breast carcinoma,"locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive)","locally advanced, inflammatory, or early stage invasive breast carcinoma",['HER2-positive'],"['Trastuzumab', 'Doxorubicin', 'Paclitaxel', 'Pertuzumab', 'Cyclophosphamide']"
415,invasive breast carcinoma,"locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive)","locally advanced, inflammatory, or early stage invasive breast carcinoma",['HER2-positive'],"['Trastuzumab', 'Fluorouracil', 'Docetaxel', 'Pertuzumab', 'Epirubicin', 'Cyclophosphamide']"
416,invasive breast carcinoma,early breast cancer,early invasive breast carcinoma,['HER2-positive'],"['Trastuzumab', 'Carboplatin', 'Docetaxel', 'Pertuzumab']"
417,invasive breast carcinoma,early breast cancer,early invasive breast carcinoma,['HER2-positive'],"['Trastuzumab', 'Fluorouracil', 'Paclitaxel', 'Pertuzumab', 'Epirubicin', 'Cyclophosphamide']"
418,invasive breast carcinoma,early breast cancer,early invasive breast carcinoma,['HER2-positive'],"['Trastuzumab', 'Doxorubicin', 'Fluorouracil', 'Docetaxel', 'Pertuzumab', 'Cyclophosphamide']"
419,invasive breast carcinoma,early breast cancer,early invasive breast carcinoma,['HER2-positive'],"['Trastuzumab', 'Doxorubicin', 'Fluorouracil', 'Paclitaxel', 'Pertuzumab', 'Cyclophosphamide']"
420,invasive breast carcinoma,early breast cancer,early invasive breast carcinoma,['HER2-positive'],"['Trastuzumab', 'Docetaxel', 'Pertuzumab', 'Epirubicin', 'Cyclophosphamide']"
421,invasive breast carcinoma,early breast cancer,early invasive breast carcinoma,['HER2-positive'],"['Trastuzumab', 'Paclitaxel', 'Pertuzumab', 'Epirubicin', 'Cyclophosphamide']"
422,invasive breast carcinoma,early breast cancer,early invasive breast carcinoma,['HER2-positive'],"['Trastuzumab', 'Doxorubicin', 'Docetaxel', 'Pertuzumab', 'Cyclophosphamide']"
423,invasive breast carcinoma,early breast cancer,early invasive breast carcinoma,['HER2-positive'],"['Trastuzumab', 'Doxorubicin', 'Paclitaxel', 'Pertuzumab', 'Cyclophosphamide']"
424,invasive breast carcinoma,early stage breast cancer,early stage invasive breast carcinoma,['HER2-positive'],"['Trastuzumab', 'Doxorubicin', 'Paclitaxel', 'Pertuzumab', 'Cyclophosphamide']"
425,invasive breast carcinoma,early stage breast cancer,early stage invasive breast carcinoma,['HER2-positive'],"['Trastuzumab', 'Fluorouracil', 'Docetaxel', 'Pertuzumab', 'Epirubicin', 'Cyclophosphamide']"
426,acute lymphoid leukemia,ph+ all,acute lymphoid leukemia,['BCR::ABL1'],"['Prednisone', 'Ponatinib', 'Vincristine', 'Methotrexate', 'Cytarabine']"
427,acute lymphoid leukemia,ph+ all,acute lymphoid leukemia,"['ABL1 p.T315I', 'BCR::ABL1']",['Ponatinib']
428,chronic myelogenous leukemia,cml,chronic myelogenous leukemia,['ABL1 p.T315I'],['Ponatinib']
429,non-small cell lung cancer,non-small cell lung cancer,non-small cell lung cancer,['v::RET'],['Pralsetinib']
430,papillary thyroid cancer,advanced or metastatic... thyroid cancer,advanced or metastatic papillary thyroid cancer,['v::RET'],['Pralsetinib']
431,non-small cell lung cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,['EGFR Exon 19 (Deletion)'],"['Erlotinib', 'Ramucirumab']"
432,non-small cell lung cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,['EGFR p.L858R'],"['Erlotinib', 'Ramucirumab']"
433,non-small cell lung cancer,locally advanced or metastatic non-small cell lung cancer,locally advanced or metastatic non-small cell lung cancer,['v::ROS1'],['Repotrectinib']
434,any solid tumor,solid tumors,any solid tumor,['v::NTRK1'],['Repotrectinib']
435,any solid tumor,solid tumors,any solid tumor,['v::NTRK2'],['Repotrectinib']
436,any solid tumor,solid tumors,any solid tumor,['v::NTRK3'],['Repotrectinib']
437,invasive breast carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['HER2-negative', 'ER positive']","['Anastrozole', 'Ribociclib']"
438,invasive breast carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['PR positive', 'HER2-negative']","['Anastrozole', 'Ribociclib']"
439,invasive breast carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['PR positive', 'HER2-negative', 'ER positive']","['Anastrozole', 'Ribociclib']"
440,invasive breast carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['HER2-negative', 'ER positive']","['Ribociclib', 'Letrozole']"
441,invasive breast carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['PR positive', 'HER2-negative']","['Ribociclib', 'Letrozole']"
442,invasive breast carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['PR positive', 'HER2-negative', 'ER positive']","['Ribociclib', 'Letrozole']"
443,invasive breast carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['HER2-negative', 'ER positive']","['Fulvestrant', 'Ribociclib']"
444,invasive breast carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['PR positive', 'HER2-negative']","['Fulvestrant', 'Ribociclib']"
445,invasive breast carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['PR positive', 'HER2-negative', 'ER positive']","['Fulvestrant', 'Ribociclib']"
446,non-hodgkin lymphoma,b-cell non-hodgkin's lymphoma (nhl),b-cell non-hodgkin lymphoma,['CD20 +'],['Rituximab']
447,non-hodgkin lymphoma,b-cell non-hodgkin's lymphoma (nhl),b-cell non-hodgkin lymphoma,['CD20 +'],"['Prednisolone', 'Vincristine', 'Rituximab', 'Cyclophosphamide']"
448,non-hodgkin lymphoma,b-cell non-hodgkin's lymphoma (nhl),b-cell non-hodgkin lymphoma,['CD20 +'],"['Doxorubicin', 'Prednisolone', 'Vincristine', 'Rituximab', 'Cyclophosphamide']"
449,non-hodgkin lymphoma,b-cell non-hodgkin's lymphoma (nhl),b-cell non-hodgkin lymphoma,['CD20 +'],"['Rituximab', 'Mitoxantrone', 'Fludarabine', 'Cyclophosphamide']"
451,non-hodgkin lymphoma,non-hodgkin's lymphoma (nhl),non-hodgkin lymphoma,['CD20 +'],"['Doxorubicin', 'Prednisone', 'Vincristine', 'Rituximab', 'Cyclophosphamide']"
452,non-hodgkin lymphoma,diffuse large b-cell non-hodgkin's lymhpoma (nhl),diffuse large b-cell non-hodgkin lymphoma,['CD20 +'],"['Doxorubicin', 'Prednisone', 'Vincristine', 'Rituximab', 'Cyclophosphamide']"
453,diffuse large b-cell lymphoma,"mature b-cell nhl and mature b-cell acute leukemia (b-al) previously untreated, advanced stage, cd20-positive, diffuse large b-cell lymphoma (dlbcl), burkitt lymphoma (bl), burkitt-like lymphoma (bll) or mature b-cell acute leukemia (b-al)","previously untreated, advanced stage, cd20-positive diffuse large b-cell lymphoma",['CD20 +'],"['Doxorubicin', 'Prednisone', 'Vincristine', 'Rituximab', 'Cyclophosphamide']"
454,burkitt lymphoma,"mature b-cell nhl and mature b-cell acute leukemia (b-al) previously untreated, advanced stage, cd20-positive, diffuse large b-cell lymphoma (dlbcl), burkitt lymphoma (bl), burkitt-like lymphoma (bll) or mature b-cell acute leukemia (b-al)","previously untreated, advanced stage, cd20-positive burkitt lymphoma",['CD20 +'],"['Doxorubicin', 'Prednisone', 'Vincristine', 'Rituximab', 'Cyclophosphamide']"
455,mature b-cell neoplasms,"mature b-cell nhl and mature b-cell acute leukemia (b-al) previously untreated, advanced stage, cd20-positive, diffuse large b-cell lymphoma (dlbcl), burkitt lymphoma (bl), burkitt-like lymphoma (bll) or mature b-cell acute leukemia (b-al)","previously untreated, advanced stage, cd20-positive mature b-cell neoplasms",['CD20 +'],"['Doxorubicin', 'Prednisone', 'Vincristine', 'Rituximab', 'Cyclophosphamide']"
456,chronic lymphocytic leukemia,chronic lymphocytic leuekmia (cll),chronic lymphocytic leukemia,['CD20 +'],"['Rituximab', 'Fludarabine', 'Cyclophosphamide']"
457,ovarian epithelial tumor,"epithelial ovarian, fallopian tube, or primary peritoneal cancer",ovarian epithelial tumor,['BRCA1 oncogenic variants'],['Rucaparib']
458,ovarian epithelial tumor,"epithelial ovarian, fallopian tube, or primary peritoneal cancer",ovarian epithelial tumor,['BRCA1 pathogenic variants'],['Rucaparib']
459,ovarian epithelial tumor,"epithelial ovarian, fallopian tube, or primary peritoneal cancer",ovarian epithelial tumor,['BRCA2 oncogenic variants'],['Rucaparib']
460,ovarian epithelial tumor,"epithelial ovarian, fallopian tube, or primary peritoneal cancer",ovarian epithelial tumor,['BRCA2 pathogenic variants'],['Rucaparib']
461,high-grade serous fallopian tube cancer,"epithelial ovarian, fallopian tube, or primary peritoneal cancer",high-grade serous fallopian tube cancer,['BRCA1 oncogenic variants'],['Rucaparib']
462,high-grade serous fallopian tube cancer,"epithelial ovarian, fallopian tube, or primary peritoneal cancer",high-grade serous fallopian tube cancer,['BRCA1 pathogenic variants'],['Rucaparib']
463,high-grade serous fallopian tube cancer,"epithelial ovarian, fallopian tube, or primary peritoneal cancer",high-grade serous fallopian tube cancer,['BRCA2 oncogenic variants'],['Rucaparib']
464,high-grade serous fallopian tube cancer,"epithelial ovarian, fallopian tube, or primary peritoneal cancer",high-grade serous fallopian tube cancer,['BRCA2 pathogenic variants'],['Rucaparib']
465,peritoneal serous carcinoma,"epithelial ovarian, fallopian tube, or primary peritoneal cancer",peritoneal serous carcinoma,['BRCA1 oncogenic variants'],['Rucaparib']
466,peritoneal serous carcinoma,"epithelial ovarian, fallopian tube, or primary peritoneal cancer",peritoneal serous carcinoma,['BRCA1 pathogenic variants'],['Rucaparib']
467,peritoneal serous carcinoma,"epithelial ovarian, fallopian tube, or primary peritoneal cancer",peritoneal serous carcinoma,['BRCA2 oncogenic variants'],['Rucaparib']
468,peritoneal serous carcinoma,"epithelial ovarian, fallopian tube, or primary peritoneal cancer",peritoneal serous carcinoma,['BRCA2 pathogenic variants'],['Rucaparib']
469,prostate adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['BRCA1 oncogenic variants'],['Rucaparib']
470,prostate adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['BRCA1 pathogenic variants'],['Rucaparib']
471,prostate adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['BRCA2 oncogenic variants'],['Rucaparib']
472,prostate adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['BRCA2 pathogenic variants'],['Rucaparib']
473,invasive breast carcinoma,unresectable locally advanced or metastatic triple-negative breast cancer (mtnbc),unresectable locally advanced or metastatic triple-negative invasive breast carcinoma,"['ER negative', 'PR negative', 'HER2-negative']",['Sacituzumab govitecan']
474,invasive breast carcinoma,locally advanced or metastatic ... breast cancer,locally advanced or metastatic invasive breast carcinoma,"['HER2-negative', 'ER positive']",['Sacituzumab govitecan']
475,invasive breast carcinoma,locally advanced or metastatic ... breast cancer,locally advanced or metastatic invasive breast carcinoma,"['PR positive', 'HER2-negative']",['Sacituzumab govitecan']
476,invasive breast carcinoma,locally advanced or metastatic ... breast cancer,locally advanced or metastatic invasive breast carcinoma,"['PR positive', 'HER2-negative', 'ER positive']",['Sacituzumab govitecan']
477,non-small cell lung cancer,locally advanced or metastatic non-small cell lung cancer,locally advanced or metastatic non-small cell lung cancer,['v::RET'],['Selpercatinib']
478,medullary thyroid cancer,advanced or metastatic medullary thyroid cancer,advanced or metastatic medullary thyroid cancer,['RET oncogenic variants'],['Selpercatinib']
479,anaplastic thyroid cancer,advanced or metastatic thyroid cancer,advanced or metastatic anaplastic thyroid cancer,['v::RET'],['Selpercatinib']
480,any solid tumor,locally advanced or metastatic solid tumors,locally advanced or metastatic any solid tumor,['v::RET'],['Selpercatinib']
481,non-small cell lung cancer,locally advanced or metastatic non-small cell lung cancer,locally advanced or metastatic non-small cell lung cancer,['KRAS p.G12C'],['Sotorasib']
482,invasive breast carcinoma,locally advanced or metastatic breast cancer,locally advanced or metastatic invasive breast carcinoma,"['HER2-negative', 'BRCA1 pathogenic variants']",['Talazoparib']
483,invasive breast carcinoma,locally advanced or metastatic breast cancer,locally advanced or metastatic invasive breast carcinoma,"['HER2-negative', 'BRCA2 pathogenic variants']",['Talazoparib']
484,non-small cell lung cancer,non-small cell lung cancer,non-small cell lung cancer,['MET Exon 14 (Splice Site)'],['Tepotinib']
485,non-small cell lung cancer,non-small cell lung cancer,non-small cell lung cancer,['MET Exon 14 (Deletion)'],['Tepotinib']
486,melanoma,unresectable or metastatic melanoma,unresectable or metastatic melanoma,['BRAF p.V600E'],['Trametinib']
487,melanoma,unresectable or metastatic melanoma,unresectable or metastatic melanoma,['BRAF p.V600K'],['Trametinib']
488,melanoma,unresectable or metastatic melanoma,unresectable or metastatic melanoma,['BRAF p.V600E'],"['Trametinib', 'Dabrafenib']"
489,melanoma,unresectable or metastatic melanoma,unresectable or metastatic melanoma,['BRAF p.V600K'],"['Trametinib', 'Dabrafenib']"
490,non-small cell lung cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,['BRAF p.V600E'],"['Trametinib', 'Dabrafenib']"
491,anaplastic thyroid cancer,locally advanced or metastatic anaplastic thyroid cancer,locally advanced or metastatic anaplastic thyroid cancer,['BRAF p.V600E'],"['Trametinib', 'Dabrafenib']"
492,any solid tumor,unresectable or metastatic solid tumors,unresectable or metastatic any solid tumor,['BRAF p.V600E'],"['Trametinib', 'Dabrafenib']"
493,"low-grade glioma, nos",low-grade glioma (lgg),"low-grade glioma, nos",['BRAF p.V600E'],"['Trametinib', 'Dabrafenib']"
494,invasive breast carcinoma,breast cancer,invasive breast carcinoma,['HER2-positive'],['Trastuzumab']
495,gastrointestinal stromal tumor,metastatic gastric or gastroesophageal junction adenocarcinoma,metastatic gastrointestinal stromal tumor,['HER2-positive'],['Trastuzumab']
496,invasive breast carcinoma,unresectable or metastatic breast cancer,unresectable or metastatic invasive breast carcinoma,['HER2-positive'],['Trastuzumab deruxtecan']
497,invasive breast carcinoma,unresectable or metastatic ... breast cancer,unresectable or metastatic invasive breast carcinoma,['HER2-low'],['Trastuzumab deruxtecan']
498,non-small cell lung cancer,unresectable or metastatic non-small cell lung cancer,unresectable or metastatic non-small cell lung cancer,['ERBB2 oncogenic variants'],['Trastuzumab deruxtecan']
499,adenocarcinoma of the gastroesophageal junction,locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma,locally advanced or metastatic adenocarcinoma of the gastroesophageal junction,['HER2-positive'],['Trastuzumab deruxtecan']
500,any solid tumor,unresectable or metastatic solid tumors,unresectable or metastatic any solid tumor,['HER2-positive'],['Trastuzumab deruxtecan']
501,invasive breast carcinoma,advanced unresectable or metastatic breast cancer,unresectable or metastatic invasive breast carcinoma,['HER2-positive'],"['Trastuzumab', 'Capecitabine', 'Tucatinib']"
502,melanoma,unresectable or metastatic melanoma,unresectable or metastatic melanoma,['BRAF p.V600E'],['Vemurafenib']
503,non-langerhans cell histiocytosis/erdheim-chester disease,erdheim-chester disease,non-langerhans cell histiocytosis/erdheim-chester disease,['BRAF p.V600E'],['Vemurafenib']
504,non-langerhans cell histiocytosis/erdheim-chester disease,erdheim-chester disease,non-langerhans cell histiocytosis/erdheim-chester disease,['BRAF p.V600K'],['Vemurafenib']
505,follicular lymphoma,follicular lymphoma,follicular lymphoma,['EZH2 p.Y646N'],['Tazemetostat']
506,follicular lymphoma,follicular lymphoma,follicular lymphoma,['EZH2 p.Y646F'],['Tazemetostat']
507,follicular lymphoma,follicular lymphoma,follicular lymphoma,['EZH2 p.Y646H'],['Tazemetostat']
508,follicular lymphoma,follicular lymphoma,follicular lymphoma,['EZH2 p.Y646S'],['Tazemetostat']
509,follicular lymphoma,follicular lymphoma,follicular lymphoma,['EZH2 p.Y646C'],['Tazemetostat']
510,follicular lymphoma,follicular lymphoma,follicular lymphoma,['EZH2 p.A862G'],['Tazemetostat']
511,follicular lymphoma,follicular lymphoma,follicular lymphoma,['EZH2 p.A692V'],['Tazemetostat']
512,prostate adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['BRCA1 pathogenic variants'],"['Enzalutamide', 'Talazoparib']"
513,prostate adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['BRCA2 oncogenic variants'],"['Enzalutamide', 'Talazoparib']"
514,prostate adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['BRCA2 pathogenic variants'],"['Enzalutamide', 'Talazoparib']"
515,prostate adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['ATM pathogenic variants'],"['Enzalutamide', 'Talazoparib']"
516,prostate adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['ATM oncogenic variants'],"['Enzalutamide', 'Talazoparib']"
517,prostate adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['ATR oncogenic variants'],"['Enzalutamide', 'Talazoparib']"
518,prostate adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['CDK12 oncogenic variants'],"['Enzalutamide', 'Talazoparib']"
519,prostate adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['ATR pathogenic variants'],"['Enzalutamide', 'Talazoparib']"
520,prostate adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['FANCA oncogenic variants'],"['Enzalutamide', 'Talazoparib']"
521,prostate adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['CHEK2 pathogenic variants'],"['Enzalutamide', 'Talazoparib']"
522,prostate adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['CHEK2 oncogenic variants'],"['Enzalutamide', 'Talazoparib']"
523,prostate adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['FANCA pathogenic variants'],"['Enzalutamide', 'Talazoparib']"
524,prostate adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['MLH1 oncogenic variants'],"['Enzalutamide', 'Talazoparib']"
525,prostate adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['PALB2 pathogenic variants'],"['Enzalutamide', 'Talazoparib']"
526,prostate adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['PALB2 oncogenic variants'],"['Enzalutamide', 'Talazoparib']"
527,prostate adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['MLH1 pathogenic variants'],"['Enzalutamide', 'Talazoparib']"
528,prostate adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['MRE11 oncogenic variants'],"['Enzalutamide', 'Talazoparib']"
529,prostate adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['RAD51C pathogenic variants'],"['Enzalutamide', 'Talazoparib']"
530,prostate adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['RAD51C oncogenic variants'],"['Enzalutamide', 'Talazoparib']"
531,prostate adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['MRE11 pathogenic variants'],"['Enzalutamide', 'Talazoparib']"
532,prostate adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['NBN oncogenic variants'],"['Enzalutamide', 'Talazoparib']"
533,prostate adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['NBN pathogenic variants'],"['Enzalutamide', 'Talazoparib']"
534,renal angiomyolipoma,renal angiomyolipoma,renal angiomyolipoma,['TSC1 oncogenic variants'],['Everolimus']
535,renal angiomyolipoma,renal angiomyolipoma,renal angiomyolipoma,['TSC2 oncogenic variants'],['Everolimus']
536,anaplastic thyroid cancer,subependymal giant cell astrocytoma,anaplastic thyroid cancer,['TSC1 oncogenic variants'],['Everolimus']
537,anaplastic thyroid cancer,subependymal giant cell astrocytoma,anaplastic thyroid cancer,['TSC2 oncogenic variants'],['Everolimus']
538,prostate adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['CDK12 pathogenic variants'],"['Enzalutamide', 'Talazoparib']"
539,non-small cell lung cancer,non-small cell lung cancer,non-small cell lung cancer,['EGFR Exon 19 (Deletion)'],['Osimertinib']
540,non-small cell lung cancer,non-small cell lung cancer,non-small cell lung cancer,['EGFR p.L858R'],['Osimertinib']
541,non-small cell lung cancer,locally advanced or metastatic non-small cell lung cancer,locally advanced or metastatic non-small cell lung cancer,['EGFR Exon 19 (Deletion)'],"['Amivantamab', 'Lazertinib']"
542,non-small cell lung cancer,locally advanced or metastatic non-small cell lung cancer,locally advanced or metastatic non-small cell lung cancer,['EGFR p.L858R'],"['Amivantamab', 'Lazertinib']"
543,non-small cell lung cancer,non-small cell lung cancer,non-small cell lung cancer,['EGFR Exon 19 (Deletion)'],"['Amivantamab', 'Lazertinib']"
544,non-small cell lung cancer,non-small cell lung cancer,non-small cell lung cancer,['EGFR p.L858R'],"['Amivantamab', 'Lazertinib']"
545,non-small cell lung cancer,non-small cell lung cancer,non-small cell lung cancer,['EGFR Exon 19 (Deletion)'],"['Carboplatin', 'Amivantamab', 'Pemetrexed']"
546,non-small cell lung cancer,non-small cell lung cancer,non-small cell lung cancer,['EGFR p.L858R'],"['Carboplatin', 'Amivantamab', 'Pemetrexed']"
547,ovarian epithelial tumor,"epithelial ovarian, fallopian tube, or primary peritoneal",ovarian epithelial tumor,['FOLR1 positive'],['Mirvetuximab soravtansine']
548,high-grade serous fallopian tube cancer,"epithelial ovarian, fallopian tube, or primary peritoneal",high-grade serous fallopian tube cancer,['FOLR1 positive'],['Mirvetuximab soravtansine']
549,peritoneal serous carcinoma,"epithelial ovarian, fallopian tube, or primary peritoneal",peritoneal serous carcinoma,['FOLR1 positive'],['Mirvetuximab soravtansine']
550,"low-grade glioma, nos",low-grade glioma (lgg),"low-grade glioma, nos",['BRAF rearrangements'],['Tovorafenib']
551,"low-grade glioma, nos",low-grade glioma (lgg),"low-grade glioma, nos",['v::BRAF'],['Tovorafenib']
552,"low-grade glioma, nos",low-grade glioma (lgg),"low-grade glioma, nos",['BRAF p.V600E'],['Tovorafenib']
553,"low-grade glioma, nos",low-grade glioma (lgg),"low-grade glioma, nos",['BRAF p.V600K'],['Tovorafenib']
554,non-small cell lung cancer,non-small cell lung cancer,non-small cell lung cancer,"['Wild type EGFR', 'Wild type ALK']","['Carboplatin', 'Paclitaxel', 'Durvalumab']"
555,non-small cell lung cancer,non-small cell lung cancer,non-small cell lung cancer,"['Wild type EGFR', 'Wild type ALK']","['Durvalumab', 'Gemcitabine', 'Cisplatin']"
556,non-small cell lung cancer,non-small cell lung cancer,non-small cell lung cancer,"['Wild type EGFR', 'Wild type ALK']","['Durvalumab', 'Pemetrexed', 'Cisplatin']"
557,non-small cell lung cancer,non-small cell lung cancer,non-small cell lung cancer,"['Wild type EGFR', 'Wild type ALK']","['Carboplatin', 'Durvalumab', 'Pemetrexed']"
558,colorectal adenocarcinoma,colorectal cancer,colorectal adenocarcinoma,['KRAS p.G12C'],"['Adagrasib', 'Cetuximab']"
559,astrocytoma,astrocytoma or oligodendroglioma,astrocytoma,['IDH1 p.R132C'],['Vorasidenib']
560,astrocytoma,astrocytoma or oligodendroglioma,astrocytoma,['IDH1 p.R132G'],['Vorasidenib']
561,astrocytoma,astrocytoma or oligodendroglioma,astrocytoma,['IDH1 p.R132H'],['Vorasidenib']
562,astrocytoma,astrocytoma or oligodendroglioma,astrocytoma,['IDH1 p.R132L'],['Vorasidenib']
563,astrocytoma,astrocytoma or oligodendroglioma,astrocytoma,['IDH1 p.R132S'],['Vorasidenib']
564,astrocytoma,astrocytoma or oligodendroglioma,astrocytoma,['IDH2 p.R172K'],['Vorasidenib']
565,astrocytoma,astrocytoma or oligodendroglioma,astrocytoma,['IDH2 p.R172M'],['Vorasidenib']
566,astrocytoma,astrocytoma or oligodendroglioma,astrocytoma,['IDH2 p.R172G'],['Vorasidenib']
567,astrocytoma,astrocytoma or oligodendroglioma,astrocytoma,['IDH2 p.R172S'],['Vorasidenib']
568,astrocytoma,astrocytoma or oligodendroglioma,astrocytoma,['IDH2 p.R172W'],['Vorasidenib']
569,oligodendroglioma,astrocytoma or oligodendroglioma,oligodendroglioma,['IDH1 p.R132C'],['Vorasidenib']
570,oligodendroglioma,astrocytoma or oligodendroglioma,oligodendroglioma,['IDH1 p.R132G'],['Vorasidenib']
571,oligodendroglioma,astrocytoma or oligodendroglioma,oligodendroglioma,['IDH1 p.R132H'],['Vorasidenib']
572,oligodendroglioma,astrocytoma or oligodendroglioma,oligodendroglioma,['IDH1 p.R132L'],['Vorasidenib']
573,oligodendroglioma,astrocytoma or oligodendroglioma,oligodendroglioma,['IDH1 p.R132S'],['Vorasidenib']
574,oligodendroglioma,astrocytoma or oligodendroglioma,oligodendroglioma,['IDH2 p.R172K'],['Vorasidenib']
575,oligodendroglioma,astrocytoma or oligodendroglioma,oligodendroglioma,['IDH2 p.R172M'],['Vorasidenib']
576,oligodendroglioma,astrocytoma or oligodendroglioma,oligodendroglioma,['IDH2 p.R172G'],['Vorasidenib']
577,oligodendroglioma,astrocytoma or oligodendroglioma,oligodendroglioma,['IDH2 p.R172S'],['Vorasidenib']
578,oligodendroglioma,astrocytoma or oligodendroglioma,oligodendroglioma,['IDH2 p.R172W'],['Vorasidenib']
579,invasive breast carcinoma,early breast cancer,early invasive breast carcinoma,"['HER2-negative', 'ER positive']","['Goserelin', 'Anastrozole', 'Ribociclib']"
580,invasive breast carcinoma,early breast cancer,early invasive breast carcinoma,"['PR positive', 'HER2-negative']","['Goserelin', 'Anastrozole', 'Ribociclib']"
581,invasive breast carcinoma,early breast cancer,early invasive breast carcinoma,"['PR positive', 'HER2-negative', 'ER positive']","['Goserelin', 'Anastrozole', 'Ribociclib']"
582,invasive breast carcinoma,early breast cancer,early invasive breast carcinoma,"['HER2-negative', 'ER positive']","['Goserelin', 'Ribociclib', 'Letrozole']"
583,invasive breast carcinoma,early breast cancer,early invasive breast carcinoma,"['PR positive', 'HER2-negative']","['Goserelin', 'Ribociclib', 'Letrozole']"
584,invasive breast carcinoma,early breast cancer,early invasive breast carcinoma,"['PR positive', 'HER2-negative', 'ER positive']","['Goserelin', 'Ribociclib', 'Letrozole']"
585,non-small cell lung cancer,non-small cell lung cancer,non-small cell lung cancer,"['Wild type EGFR', 'Wild type ALK']","['Nivolumab', 'Pemetrexed', 'Cisplatin']"
586,non-small cell lung cancer,non-small cell lung cancer,non-small cell lung cancer,"['Wild type EGFR', 'Wild type ALK']","['Nivolumab', 'Gemcitabine', 'Cisplatin']"
587,non-small cell lung cancer,non-small cell lung cancer,non-small cell lung cancer,"['Wild type EGFR', 'Wild type ALK']","['Carboplatin', 'Nivolumab', 'Ipilimumab', 'Pemetrexed']"
588,non-small cell lung cancer,non-small cell lung cancer,non-small cell lung cancer,"['Wild type EGFR', 'Wild type ALK']","['Nivolumab', 'Ipilimumab', 'Pemetrexed', 'Cisplatin']"
589,non-small cell lung cancer,non-small cell lung cancer,non-small cell lung cancer,"['Wild type EGFR', 'Wild type ALK']","['Carboplatin', 'Paclitaxel', 'Nivolumab', 'Ipilimumab']"
591,colorectal adenocarcinoma,colorectal cancer,colorectal adenocarcinoma,['dMMR'],"['Nivolumab', 'Ipilimumab']"
592,colorectal adenocarcinoma,colorectal cancer,colorectal adenocarcinoma,['MSI-H'],['Nivolumab']
593,colorectal adenocarcinoma,colorectal cancer,colorectal adenocarcinoma,['dMMR'],['Nivolumab']
594,invasive breast carcinoma,metastatic breast cancer,metastatic invasive breast carcinoma,"['HER2-negative', 'ER positive', 'PIK3CA somatic variants']","['Inavolisib', 'Fulvestrant', 'Palbociclib']"
595,invasive breast carcinoma,metastatic breast cancer,metastatic invasive breast carcinoma,"['PR positive', 'HER2-negative', 'PIK3CA somatic variants']","['Inavolisib', 'Fulvestrant', 'Palbociclib']"
596,invasive breast carcinoma,metastatic breast cancer,metastatic invasive breast carcinoma,"['PR positive', 'HER2-negative', 'ER positive', 'PIK3CA somatic variants']","['Inavolisib', 'Fulvestrant', 'Palbociclib']"
597,adenocarcinoma of the gastroesophageal junction,gastric or gastroesophageal junction adenocarcinoma,adenocarcinoma of the gastroesophageal junction,"['HER2-negative', 'CLDN18.2 >= 75%']","['Oxaliplatin', 'Fluorouracil', 'Zolbetuximab']"
598,adenocarcinoma of the gastroesophageal junction,gastric or gastroesophageal junction adenocarcinoma,adenocarcinoma of the gastroesophageal junction,"['HER2-negative', 'CLDN18.2 >= 75%']","['Oxaliplatin', 'Zolbetuximab', 'Capecitabine']"
599,intraductal papillary neoplasm of the bile duct,biliary tract cancer (btc),intraductal papillary neoplasm of the bile duct,['HER2-positive'],['Zanidatamab']
600,intracholecystic papillary neoplasm,biliary tract cancer (btc),intracholecystic papillary neoplasm,['HER2-positive'],['Zanidatamab']
601,cholangiocarcinoma,biliary tract cancer (btc),cholangiocarcinoma,['HER2-positive'],['Zanidatamab']
602,non-small cell lung cancer,non-small cell lung cancer,non-small cell lung cancer,['v::NRG1'],['Zenocutuzumab']
603,pancreatic adenocarcinoma,pancreatic adenocarcinoma,pancreatic adenocarcinoma,['v::NRG1'],['Zenocutuzumab']
604,non-small cell lung cancer,non-small cell lung cancer,non-small cell lung cancer,['v::ALK'],['Ensartinib']
605,colorectal adenocarcinoma,metastatic colorectal cancer,metastatic colorectal adenocarcinoma,['BRAF p.V600E'],"['Oxaliplatin', 'Fluorouracil', 'Cetuximab', 'Encorafenib']"
606,"chronic myeloid leukemia, bcr-abl1+",philadelphia chromosome-positive chronic myeloid leukemia (ph+ cml),"philadelphia chromosome-positive chronic myeloid leukemia, bcr-abl1+",['BCR::ABL1'],['Asciminib']
607,"chronic myeloid leukemia, bcr-abl1+",philadelphia chromosome-positive chronic myeloid leukemia (ph+ cml),"philadelphia chromosome-positive chronic myeloid leukemia, bcr-abl1+",['BCR::ABL1'],['Asciminib']
608,non-small cell lung cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,"['Wild type EGFR', 'Wild type ALK']","['Tremelimumab', 'Carboplatin', 'Durvalumab', 'Pemetrexed']"
609,non-small cell lung cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,"['Wild type EGFR', 'Wild type ALK']","['Tremelimumab', 'Durvalumab', 'Pemetrexed', 'Cisplatin']"
610,non-small cell lung cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,"['Wild type EGFR', 'Wild type ALK']","['Tremelimumab', 'Carboplatin', 'Durvalumab', 'Gemcitabine']"
611,non-small cell lung cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,"['Wild type EGFR', 'Wild type ALK']","['Tremelimumab', 'Durvalumab', 'Gemcitabine', 'Cisplatin']"
612,non-small cell lung cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,"['Wild type EGFR', 'Wild type ALK']","['Tremelimumab', 'Carboplatin', 'Durvalumab', 'Nab-paclitaxel']"
613,acute lymphoid leukemia,acute leukemia,acute lymphoid leukemia,['t(KMT2A;v)'],['Revumenib']
614,acute myeloid leukemia,acute leukemia,acute myeloid leukemia,['t(KMT2A;v)'],['Revumenib']
615,burkitt lymphoma,acute leukemia,burkitt lymphoma,['t(KMT2A;v)'],['Revumenib']
616,acute leukemias of ambiguous lineage,acute leukemia,acute leukemias of ambiguous lineage,['t(KMT2A;v)'],['Revumenib']
617,invasive breast carcinoma,early breast cancer,early invasive breast carcinoma,"['PR positive', 'HER2-negative']","['Abemaciclib', 'Letrozole']"
618,invasive breast carcinoma,early breast cancer,early invasive breast carcinoma,"['PR positive', 'HER2-negative', 'ER positive']","['Anastrozole', 'Abemaciclib']"
619,invasive breast carcinoma,early breast cancer,early invasive breast carcinoma,"['HER2-negative', 'ER positive']","['Anastrozole', 'Abemaciclib']"
620,invasive breast carcinoma,early breast cancer,early invasive breast carcinoma,"['PR positive', 'HER2-negative']","['Anastrozole', 'Abemaciclib']"
621,invasive breast carcinoma,early breast cancer,early invasive breast carcinoma,"['PR positive', 'HER2-negative', 'ER positive']","['Exemestane', 'Abemaciclib']"
622,invasive breast carcinoma,early breast cancer,early invasive breast carcinoma,"['HER2-negative', 'ER positive']","['Exemestane', 'Abemaciclib']"
623,invasive breast carcinoma,early breast cancer,early invasive breast carcinoma,"['PR positive', 'HER2-negative']","['Exemestane', 'Abemaciclib']"
624,colorectal adenocarcinoma,colorectal cancer,colorectal adenocarcinoma,['MSI-H'],"['Nivolumab', 'Ipilimumab']"
625,non-small cell lung cancer,non-small cell lung cancer,non-small cell lung cancer,['v::ROS1'],['Taletrectinib']
626,lung non-squamous non-small cell carcinoma,non-squamous non-small cell lung cancer,lung non-squamous non-small cell carcinoma,['c-Met >= 50%'],['Telisotuzumab Vedotin']
627,low-grade serous ovarian cancer,low-grade serous ovarian cancer (lgsoc),low-grade serous ovarian cancer,['KRAS p.G12C'],"['Avutometinib', 'Defactinib']"
628,low-grade serous ovarian cancer,low-grade serous ovarian cancer (lgsoc),low-grade serous ovarian cancer,['KRAS p.G12V'],"['Avutometinib', 'Defactinib']"
629,apl with pml-rara,low-risk acute promyelocytic leukemia (apl),low-risk apl with pml-rara,['t(15;17)'],['Arsenic trioxide']
630,apl with pml-rara,acute promyelocytic leukemia (apl),apl with pml-rara,['t(15;17)'],['Arsenic trioxide']
631,chronic myelogenous leukemia,ph+ cml-cp and cml-ap,chronic myelogenous leukemia,['BCR::ABL1'],['Nilotinib']
632,"chronic myeloid leukemia, bcr-abl1+",ph+ cml-cp and cml-ap,"chronic myeloid leukemia, bcr-abl1+",['BCR::ABL1'],['Nilotinib']
634,chronic myelogenous leukemia,philadelphia chromosome-positive chronic myeloid leukemia (ph+ cml),philadelphia chromosome-positive chronic myelogenous leukemia,['BCR::ABL1'],['Asciminib']
635,head and neck squamous cell carcinoma,head and neck squamous cell cancer,head and neck squamous cell carcinoma,['PD-L1 (CPS) >= 1'],['Pembrolizumab']
636,non-small cell lung cancer,non-small cell lung cancer,non-small cell lung cancer,['EGFR somatic variants'],['Datopotamab deruxtecan']
637,non-small cell lung cancer,non-small cell lung cancer,non-small cell lung cancer,['EGFR Exon 19 (Deletion)'],['Datopotamab deruxtecan']
638,non-small cell lung cancer,non-small cell lung cancer,non-small cell lung cancer,['EGFR p.L858R'],['Datopotamab deruxtecan']
639,non-small cell lung cancer,non-small cell lung cancer,non-small cell lung cancer,['EGFR p.T790M'],['Datopotamab deruxtecan']
640,invasive breast carcinoma,non-small cell lung cancer,invasive breast carcinoma,['EGFR Exon 20 (Insertion)'],['Datopotamab deruxtecan']
641,invasive breast carcinoma,breast cancer,invasive breast carcinoma,"['HER2-negative', 'ER positive']",['Datopotamab deruxtecan']
642,non-small cell lung cancer,breast cancer,non-small cell lung cancer,"['PR positive', 'HER2-negative']",['Datopotamab deruxtecan']
643,invasive breast carcinoma,breast cancer,invasive breast carcinoma,"['PR positive', 'HER2-negative', 'ER positive']",['Datopotamab deruxtecan']
644,non-small cell lung cancer,non-small cell lung cancer (nsclc),non-small cell lung cancer,['EGFR Exon 20 (Insertion)'],['Sunvozertinib']
645,lung non-squamous non-small cell carcinoma,non-squamous non-small cell lung cancer,lung non-squamous non-small cell carcinoma,['ERBB2 TKD activating variants'],['Zongertinib']
